6009 rock cliff lane

City, State or Zip
Alexandria, VA 22315-4631

Country
United States

3206 N St NW

City, State or Zip
Washington, DC 20007-282

Country
United States

Get Directions

Shopping for a New Car?

Cell surface tagging and a suicide mechanism in a single chimeric human protein.

Amara J F; Courage N L; Gilman M
ARIAD Pharmaceuticals, Inc., Cambridge, MA 02139, USA.

Human gene therapy (UNITED STATES) Nov 1 1999, 10 (16) p2651-5, ISSN 1043-0342 Journal Code: 9008950
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

Many therapeutic uses of gene-modified cells could benefit from inclusion of a surface marker for immunoselecting transduced cells. Another desired feature is a failsafe mechanism to ablate engineered cells if required. We describe here a system that combines a cell surface tag and an inducible apoptosis mechanism in a single protein. Spencer et al. (Curr. Biol. 1996;6:839-847) described an inducible cell suicide gene containing a myristoylation sequence, the human protein FKBP12, and the intracellular domain of Fas. Cells expressing this protein apoptose on treatment with a cell-permeable chemical dimerizing agent that binds two FKBP domains and cross-links the chimeric Fas proteins. We modified this system by anchoring a Fas-FKBP construct to the membrane with the extracellular and transmembrane domains of the low-affinity nerve growth **factor receptor** (LNGFR), thereby uniting cell surface tagging with the inducible apoptosis mechanism. Cells retrovirally transduced with this construct apoptosed on exposure to a chemical dimerizer, AP1903 (Clackson et al., Proc. Natl. Acad. Sci. U.S.A. 1998;95:10437-10442). The LNGFR-tagged construct showed an unpredicted clear advantage over the myristoylation-anchored construct in its efficiency of signaling in HT1080 cells. This linked marker and failsafe mechanism may have particularly attractive safety properties for gene therapy. The use of gene-modified cells in basic research and clinical studies is enhanced by the use of a selectable surface marker for immunoselection of transduced cells. Another desired feature for gene and cell therapies is an inducible suicide system to eliminate transduced cells when necessary. Spencer et al. (Curr. Biol. 1996;6:839-847) described a potential failsafe mechanism whereby exposure of cells to a chemical dimerizing agent activates the Fas-mediated apoptotic pathway. In this system, the intracellular signaling domain of Fas is linked to one or more copies of the human protein FKBP12. Treatment of engineered cells with a cell-permeable chemical dimerizing agent that simultaneously binds to two **FKBP** domains cross-links the **chimeric** Fas protein and induces apoptosis. Here, we modify the system by anchoring a Fas-FKBP construct to the membrane with the extracellular domain of the low-affinity nerve growth **factor receptor** (LNGFR), to unite cell surface tagging of transduced cells with the inducible apoptosis mechanism. Cells retrovirally transduced with this construct undergo apoptosis on exposure to a chemical dimerizer, AP1903. A linked marker and failsafe mechanism may have particularly attractive safety properties for gene therapy.

Small-molecule control of insulin and PDGF receptor signaling and the role of membrane attachment.

Yang J; Symes K; Mercola M; Schreiber S L
Howard Hughes Medical Institute, Department of Chemistry and Chemical Biology, Harvard University, 12 Oxford Street, Cambridge, Massachusetts, 02138, USA.

Current biology : CB (ENGLAND) Jan 1 1998, 8 (1) p11-8, ISSN 0960-9822 Journal Code: 9107782
Contract/Grant No.: GM-52067; GM; NIGMS; HL59502; HL; NHLBI
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

BACKGROUND: Receptor tyrosine kinases (RTKs) regulate the proliferation, differentiation and metabolism of cells, and play key roles in tissue repair, tumorigenesis and development. To facilitate the study of RTKs, we have made conditional alleles that encode monomeric forms of the normally heterotetrameric insulin receptor and monomeric platelet-derived growth **factor** (PDGF) beta **receptors** fused to the FK506-binding protein 12 (FKBP12). The chimeric receptors can be induced to undergo dimerization or oligomerization by a small synthetic molecule called FK1012, and the

consequences were studied in cells and embryonic tissues. RESULTS: When equipped with an amino-terminal plasma membrane localization sequence and expressed in HEK293 cells, these chimeric receptors could signal to downstream targets as indicated by the FK1012-dependent activation of p70 S6 kinase (p70(S6k)) and mitogen-activated protein (MAP) kinase. In Xenopus embryos, the engineered PDGF receptor protein induced the formation of mesoderm from animal-pole explants in an FK1012-dependent manner. A cytosolic variant of the protein underwent efficient transphosphorylation, yet failed to activate appreciably either p70(S6k) or MAP kinase following treatment with FK1012. These results provide evidence of a requirement for membrane localization of RTKs, consistent with current models of RTK signaling. CONCLUSION: We have developed an approach using the small molecule FK1012 to conditionally activate **chimeric** proteins containing **FKBP** **fused** to the insulin receptor or to the PDGF beta receptor. Using this system, we were able to induce mesoderm formation in Xenopus animal-cap tissue and to demonstrate that membrane localization is required for RTK signaling in transfected cells. This system should allow the further dissection of RTK-mediated pathways.

FK1012 growth Ldb+

Redesigning an FKBP-ligand interface to generate chemical dimerizers with novel specificity.

Clackson T; Yang W; Rozamus L W; Hatada M; Amara J F; Rollins C T; Stevenson L F; Magari S R; Wood S A; Courage N L; Lu X; Cerasoli F; Gilman M; Holt D A

ARIAD Gene Therapeutics, Inc., 26 Landsdowne Street, Cambridge, MA 02139, USA.

Proceedings of the National Academy of Sciences of the United States of America (UNITED STATES) Sep 1 1998, 95 (18) p10437-42, ISSN 0027-8424 Journal Code: 7505876

Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

Apoptosis

FKBP ligand homodimers can be used to activate signaling events inside cells and animals that have been engineered to express fusions between appropriate signaling domains and FKBP. However, use of these dimerizers in vivo is potentially limited by ligand binding to endogenous FKBP. We have designed ligands that bind specifically to a mutated FKBP over the wild-type protein by remodeling an FKBP-ligand interface to introduce a specificity binding pocket. A compound bearing an ethyl substituent in place of a carbonyl group exhibited sub-nanomolar affinity and 1,000-fold selectivity for a mutant FKBP with a compensating truncation of a phenylalanine residue. Structural and functional analysis of the new pocket showed that recognition is surprisingly relaxed, with the modified ligand only partially filling the engineered cavity. We incorporated the specificity pocket into a **fusion** protein containing **FKBP** and the intracellular domain of the Fas **receptor** . Cells expressing this modified chimeric protein potently underwent apoptosis in response to AP1903, a homodimer of the modified ligand, both in culture and when implanted into mice. Remodeled dimerizers such as AP1903 are ideal reagents for controlling the activities of cells that have been modified by gene therapy procedures, without interference from endogenous FKBP.

FKBP/FasR AP1903

Controlling programmed cell death with a cyclophilin-cyclosporin-based chemical inducer of dimerization.

Belshaw P J; Spencer D M; Crabtree G R; Schreiber S L

Howard Hughes Medical Institute, Department of Chemistry and Chemical Biology, Harvard University, Cambridge, MA 02138, USA. sls@slsiris.harvard.edu

Chemistry & biology (ENGLAND) Sep 1996, 3 (9) p731-8, ISSN 1074-5521 Journal Code: 9500160

Contract/Grant No.: GM52067; GM; NIGMS
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

cyclophilin/FasR
md.CsA → apoptosis

BACKGROUND: Cell death can occur either from physical damage (necrosis) or cellular suicide (apoptosis). Apoptosis is essential for the development

of multicellular organisms and disregulated apoptosis underlies many human diseases. The Fas **receptor** (Fas) is a membrane signaling protein that mediates a death signal following its aggregation by the Fas ligand. We have described methods to induce the association of proteins using cell-permeable molecules called chemical inducers of dimerization (CIDs). Here we describe the synthesis of a novel CID, (CsA)2, that has two identical protein-binding surfaces derived from the immunosuppressant cyclosporin A (CsA). We use this CID to deliver a death signal to cells expressing a **fusion** protein containing **cyclophilin** (CyP, the protein **receptor** for cyclosporin) and the cytoplasmic signaling domain of Fas. RESULTS: (CsA)2 was synthesized in six synthetic steps and 30% overall yield from cyclosporin. It binds to two CyP proteins simultaneously, but does not inhibit T-cell signaling, presumably because the (CsA)2-CyP complex does not bind to calcineurin. Jurkat cells stably transfected with constructs encoding myristoylated CyP-Fas fusion proteins undergo apoptosis in response to nanomolar quantities of (CsA)2. Constructs containing a mutation in the myristoylation signal are defective for signaling. CONCLUSIONS: The Fas signaling pathway can be activated with a cell-permeable CID derived from CsA in cells expressing an appropriately engineered Fas construct, which must be localized at the membrane. This new class of homodimerizing CIDs will be useful for in-depth analysis of protein association events in complex systems, including transgenic animals. Now that several CIDs with distinct dimerization characteristics are available, it should be possible to induce the activation of multiple pathways with complete specificity.

Dexamethasone negatively regulates the activity of a chimeric dihydrofolate reductase/glucocorticoid receptor protein.

Israel D I; Kaufman R J
Genetics Institute, Cambridge, MA 02140.

Proceedings of the National Academy of Sciences of the United States of America (UNITED STATES) May 1 1993, 90 (9) p4290-4, ISSN 0027-8424
Journal Code: 7505876
Document type: Journal Article
Languages: ENGLISH
Main Citation Owner: NLM
Record type: Completed

A chimeric gene was constructed encoding the entire murine dihydrofolate reductase (DHFR) protein with a carboxyl-terminal extension encompassing amino acids 494-795 of the rat glucocorticoid **receptor** (GR). The **chimeric DHFR** /GR gene encoded a functional DHFR protein, as measured by the ability to transform DHFR-deficient Chinese hamster ovary (CHO) cells to a DHFR-positive phenotype. The DHFR/GR protein bound [3H]dexamethasone with a similar affinity as wild-type GR. Selection of stable CHO transformants in increasing concentrations of methotrexate resulted in increased expression of DHFR/GR. Addition of dexamethasone, a synthetic glucocorticoid agonist, decreased the activity of the chimeric protein, as measured by colony formation in selective medium, binding of fluoresceinated methotrexate, and direct enzymatic assay for DHFR. Addition of RU486, a glucocorticoid antagonist, antagonized the effect of dexamethasone. In the absence of dexamethasone, the chimeric protein was primarily localized to the cytoplasm. In the presence of dexamethasone or RU486, DHFR/GR translocated into the nucleus. However, RU486 did not decrease DHFR activity, distinguishing subcellular location from functional activity. These results demonstrate that glucocorticoids negatively affect the function of DHFR/GR.

Title: Small-molecule control of insulin and PDGF receptor signaling and the role of membrane attachment (ABSTRACT AVAILABLE)

Author(s): Yang JX; Symes K; Mercola M; Schreiber SL (REPRINT)
Corporate Source: HARVARD UNIV,HOWARD HUGHES MED INST, DEPT CHEM & BIOL CHEM, 12 OXFORD ST/CAMBRIDGE//MA/02138 (REPRINT); HARVARD UNIV,HOWARD HUGHES MED INST, DEPT CHEM & BIOL CHEM/CAMBRIDGE//MA/02138; HARVARD UNIV,SCH MED, DEPT CELL BIOL/BOSTON//MA/02115

Journal: CURRENT BIOLOGY, 1998, V8, N1 (JAN 1), P11-18
ISSN: 0960-9822 Publication date: 19980101
Publisher: CURRENT BIOLOGY LTD, 34-42 CLEVELAND STREET, LONDON, ENGLAND W1P 6LB
Language: English Document Type: ARTICLE

Abstract: Background: Receptor tyrosine kinases (RTKs) regulate the proliferation, differentiation and metabolism of cells, and play key roles in tissue repair, tumorigenesis and development. To facilitate the study of RTKs, we have made conditional alleles that encode monomeric forms of the normally heterotetrameric insulin receptor and monomeric platelet-derived growth factor (PDGF) beta receptors fused to the FK506-binding protein 12 (FKBP12). The chimeric receptors can be induced to undergo dimerization or oligomerization by a small synthetic molecule called FK1012, and the consequences were studied in cells and embryonic tissues,

Results: When equipped with an amino-terminal plasma membrane localization sequence and expressed in HEK293 cells, these chimeric receptors could signal to downstream targets as indicated by the FK1012-dependent activation of p70 S6 kinase (p70(S6k)) and mitogen-activated protein (MAP) kinase, In Xenopus embryos, the engineered PDGF receptor protein induced the formation of mesoderm from animal-pole explants in an FK1012-dependent manner. A cytosolic variant of the protein underwent efficient transphosphorylation, yet failed to activate appreciably either p70(S6k) Or MAP kinase following treatment with FK1012, These results provide evidence of? a requirement for membrane localization of RTKs, consistent with current models of RTK signaling.

Conclusion: We have developed an approach using the small molecule FK1012 to conditionally activate **chimeric** proteins containing **FKBP fused** to the insulin **receptor** or to the PDGF beta **receptor** . Using this system, we were able to induce mesoderm formation in Xenopus animal-cap tissue and to demonstrate that membrane localization is required for RTK signaling in transfected cells, This system should allow the further dissection of RTK-mediated pathways.

US-PAT-NO: 6316418
DOCUMENT-IDENTIFIER: US 6316418 B1

TITLE: Regulated apoptosis

DATE-ISSUED: November 13, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Crabtree; Gerald	Woodside	CA	N/A	N/A
Schreiber; Stuart	Boston	MA	N/A	N/A
Spencer; David	Houston	TX	N/A	N/A
Wandless; Thomas	Palo Alto	CA	N/A	N/A
Belshaw; Peter	Somerville	MA	N/A	N/A
Ho; Steffan N	San Diego	CA	N/A	N/A

ASSIGNEE INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY	TYPE CODE
Board of Trustees of Leland Stanford Junior University	Stanford	CA	N/A	N/A	02
President and Fellows of Harvard College	Cambridge	MA	N/A	N/A	02

APPL-NO: 09/ 302629

DATE FILED: April 30, 1999

PARENT-CASE:

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a continuation of U.S. Ser. No. 09/087,811, filed May 29, 1998 (U.S. Pat. No. 6,054,436), which is a continuation of U.S. Ser. No. 08/292,597,

filed Aug. 18, 1994 (U.S. Pat. No. 5,834,266), which is a continuation-in-part of Ser. No. 08/179,143 filed Jan. 7, 1994 (abandoned), which is a continuation-in-part of Ser. No. 08/093,499 filed Jul. 16, 1993 (abandoned); and a continuation-in-part of Ser. No. 08/196,043 filed Feb. 11, 1994 (abandoned), which is a continuation-in-part of Ser. No. 08/179,748 filed Jan. 7, 1994 (abandoned), which is a continuation-in-part of Ser. No. 08/092,977 filed Jul. 16, 1993 (abandoned), which is a continuation-in-part of Ser. No. 08/017,931 filed Feb. 12, 1993 (abandoned). The contents of each of these applications is hereby incorporated by referenced into the present disclosure. The full contents of related cases PCT/US94/01617, PCT/US94/01660 and PCT/US94/08008 are also incorporated by reference into the present disclosure.

INT-CL: [07] A61K031/70,A61K038/12 ,A61K048/00 ,C12N005/10

US-CL-ISSUED: 514/31;424/93.2 ;424/93.21 ;435/325 ;514/9

US-CL-CURRENT: 514/31; 424/93.2 ; 424/93.21 ; 435/325 ; 514/9

FIELD-OF-SEARCH: 424/93.2; 424/93.21 ; 435/325 ; 435/372.3 ; 435/455 ; 514/9 ; 514/31

REF-CITED:

U.S. PATENT DOCUMENTS

PAT-NO	ISSUE-DATE	PATENTEE-NAME	US-CL
5171671	December 1992	Evans et al.	435/69.1
	N/A	N/A	
6054436	April 2000	Crabtree et al.	514/31
	N/A	N/A	

FOREIGN PATENT DOCUMENTS

FOREIGN-PAT-NO	PUBN-DATE	COUNTRY	US-CL
0 594 847 A1	May 1994	EP	

WO 92/01052	January 1992	WO
WO 93/23550	November 1993	WO
WO 93/25533	December 1993	WO

OTHER PUBLICATIONS

Ishizaka-Ikeda, E., et al., "Signal transduction mediated by growth hormone receptor and its chimeric molecules with the granulocyte colony-stimulating factor receptor" Proc. Natl. Acad. Sci, USA, 90(1):123-7, 1993.

Letourneur, F., et al., "T-cell and basophil activation through the cytoplasmic tail of T-cell-receptor zeta family proteins" Proc. Natl. Acad. Sci, USA, 88(20): 8905-9, 1991.

Letourneur, F., et al., "Activation of T-cells by a tyrosine kinase activation domain in the cytoplasmic tail of CD3 epsilon" Science 255:79-82, 1992.

Harding et al. (1989) "A Receptor for the Immunosuppressant FK506 is a cis-trans Peptidyl-Prolyl Isomerase" Nature 341, 758.

Schreiber et al. (1991) "Immunophilin-Ligand Complexes as Probes of Intracellular Signaling Pathways" Transplantation Proceedings, 23, 2839.

Schreiber et al. (1992) "Molecular Recognition of Immunophilins and Immunophilin-Ligand Complexes" Tetrahedron 148: 2545-2558.

Schreiber et al. (1991) "Protein Overproduction for Organic Chemists" Tetrahedron, 47, 2543-2562.

Rosen et al. (1992)"Natural Products as Probes of Cellular Function: Studies of Immunophilins" Angew. Chemie, Int. Ed. Eng., 31, 384-400.

Bram et al. (1993) "Identification of the Immunophilins

Capable of
Mediating Inhibition of Signal Transduction by Cyclopsorin A and FK506: Roles
of Calcineurin Binding and Cellular Location" Mol. Cell Biol., 13, 4760-4769.

Selvakumaran et al. (1993) "Myeloblastic leukemia cells conditionally
blocked by Myc-estrogen receptor chimeric transgenes for terminal
differentiation coupled to growth arrest and apoptosis" Blood, 81:2257.

Wandless T.J. (1993) "Turning genes on and off using FKBP and FK506"
Doctoral Thesis.

Standaert R.F. (1992) "Biochemical and structural studies of the FK506- and
rapamycin-binding proteins (FKBPs)", Abstract of Doctoral Thesis.

Bierer et al. (1990) "Mechanisms of Immunosuppression by FK506:
Preservation of T Cell Transmembrane Signal Transduction" Transplantation, 49,
1168.

Rosen et al. (1990) "Inhibition of FKBP Rotamase Activity by
Immunosuppressant FK506: A Twisted Amide Surrogate" Science, 248, 863.

Bierer et al. (1990) "Two Distinct Signal Transmission Pathways in T
Lymphocytes are Inhibited by Complexes Formed Between an Immunophilin and
Either FK506 or Rapamycin" PNAS U. S. A., 87, 9231.

Albers et al. (1990) "Substrate Specificity for the Human Rotamase FKBP: A
View of FK506 and Rapamycin as Leucine (twisted amide)-Proline Mimics" J. Org.
Chem., 55, 4984.

Mattila et al. "The actions of cyclosporin A and FK506 suggest a novel step
in the activation of T lymphocytes" EMBO J. 9:4425.

Bierer et al. (1990) "Probing Immunosuppressant Action with a Nonnatural Immunophilin Ligand" Science, 250, 556.

Schreiber S.L. (1991) "Chemistry and Biology of the Immunophilins and Their Immunosuppressive Ligands" Science, 251, 283.

Fretz et al. (1991) "Rapamycin and FK506 Binding Proteins (Immunophilins)" J. Am. Chem. Soc., 113, 1409.

Bierer et al. (1991) "The Effect of the Immunosuppressant FK506 on Alternate Pathways of T Cell Activation" Eur. J. Immunol., 21, 439-445.

Wandless et al.(1991) "FK506 and Rapamycin Binding to FKBP: Common Elements Involved in Immunophilin-Ligand Complexation" J. Am. Chem. Soc., 113, 2339-2341.

Lane et al. (1991) "Complete Amino Acid Sequence of the FK506 and Rapamycin Binding Protein, FKBP, Isolated from Calf Thymus" J. Prot. Chem., 10, 151-160.

Hultsch et al. (1991) "Inhibition of IgE Receptor-Mediated Exocytosis from Rat Basophilic Leukemia Cells by FK506 is Reversed by Rapamycin: Evidence for Common Signaling Pathways in Mast Cells and T Lymphocytes" FASEB J., 5, A1008 (3705).

Rosen et al. (1991) "Proton and Nitrogen Sequential Assignments and Secondary Structure Determination of the Human FK506 and Rapamycin Binding Protein" Biochemistry, 30, 4774-4789.

Michnick et al. (1991) "Solution Structure of FKBP, a Rotamase Enzyme and Receptor for FK506 and Rapamycin" Science 252, 836-839.

Van Duyne et al.(1991) "Atomic Structure of FKBP-FK506,

an
Immunophilin-Immunosuppressant Complex" Science , 252, 839-842.

Albers et al. (1991) "FKBP, Thought to Be Identical to PKCI-2, Does Not
Inhibit Protein Kinase C" BioMed. Chem. Lett., 1, 205-210.

Albers et al. (1991)"The Relationship of FKBP to PKCI-2" Nature, 351, 527.

Hultsch et al. (1991) "Immunophilin Ligands Demonstrate Common Features of
Signal Transduction Leading to Exocytosis or Transcription" PNAS USA., 88,
6229-6233.

Van Duyne et al. (1991) "Atomic Structure of the Rapamycin human
immunophilin FKBP-12 complex" J. Am. Chem. Soc., 113, 7433.

Ullman et al. (1991) "Site of action of cyclosporine and FK506 in the
pathways of communication between the T-lymhocyte antigen receptor and the
early activation genes" Transplant. Proceed., 23, 2845.

Galat et al. (1992) "A Rapamycin-Selective 25 kDa Immunophilin"
Biochemistry, 31, 2427-2434.

Schreiber et al.(1992) "The Mechanism of Action of Cyclosporin A and FK506"
Immunology Today, 13, 136-142.

Liu et al. (1992) "Inhibiton of T Cell Signaling by Immunophilin-Ligand
Complexes Correlates With Loss of Calcineurin Phosphatase Activity"
Biochemistry, 31, 3896-3901.

Francavilla et al. (1992) "Inhibiton of Liver, Kidney, and Intestine
Regeneration by Rapamycin" Transplantation, 53, 496-498.

Tai et al. (1992) "Association of a 59-Kilodalton Immunophilin with the
Glucocorticoid Receptor Complex" Science, 256, 1315-1318.

Schreiber S.L.(1992) "Immunophilin-Sensitive Phosphatase Action in Cell Signaling Pathways" Cell, 70, 365-368.

Kaye et al. (1992) "Effects of Cyclosporin A and FK506 of Fce Receptor type I-Initiated Increases in Cytokine mRNA in Mouse Bone Marrow-Derived Progenito Mast Cells: Resistance to FK506 is Associated with a Deficiency in FKBP12", PNAS USA, 89, 8542-8546.

DiLella et al.(1992) "Chromoxomal Band Assignments of the Genes Encoding Human FKBP12 and FKBP13" Biochem. Biophys. Res. Commun., 189, 819-823.

Chung et al. (1992) "Rapamycin-FKBP specifically blocks growth-dependent activation of and signalling by the 70 kd S6 protein kinases" Cell, 69, 1227.

Flanagan et al. (1992) "Intracellular signal transmission: a novel role for the prolyl isomerases" J. Cell. Biochem. Suppl. 0 (16 Part A), 61, Abstract #B005.

Kao et al. (1992) "Nuclear target of cyclosporin A and FK506 action is specifically bound by a heterodimeric protein comprising molecular weights 90K and 45K" J. Cell. Biochem. Suppl. 0 (16 Part B), 239, Abstract #H 523.

Flanagan et al. (1992) "Nuclear association of a transcription factor essential for T cell activation by cyclosporin A and FK506" J. Cell. Biochem. Suppl. 0 (16 Part B), 237, Abstract #H514.

Serafini et al. (1992) "Selection and characterization of mutants in a signal transduction/transmission pathway" J. Cell. Biochem. Suppl. 0 (6 Part A) 89, Abstract #B234.

Yang et al. (1993) "A Composite FKBP12-FK506 Surface That Contacts
Calcineurin" J. Am. Chem. Soc., 115, 819-820.

Rosen et al. (1993) "Activation of an Inactive Immunophilin by Mutagenesis"
J. Am. Chem. Soc., 115, 821-822.

Van Duyne et al. (1993) "Atomic Structures of the Human Immunophilin FKBP12
Complexes with FK506- and Rapamycin" J. Mol. Biol., 229, 105-124.

Tai et al. (1993) "P59 (FK506 Binding Protein 59) Interaction with Heat
Shock Proteins is Highly Conserved and May Involve Proteins Other Than Steroid
Receptors" Biochemistry, 32, 8842-8847.

Alberg et al. (1993) "Structure-Based Design of a Cyclophilin-Calcineurin
Bridging Ligand" Science, 262, 248-250.

Andrus et al. (1993) "Structure-Based Design of an Acyclic Ligand That
Bridges FKBP12 and Calcineurin" J. Am. Chem. Soc., 115, 10420-10421.

Albers et al. (1993) "An FKBP-Rapamycin Sensitive, Cyclin-Dependent Kinase
Activity That Correlates With the FKBP Rapamycin-Induced G1 Arrest Point in
MG-63 Cells" Annals of N. Y. Acad. Sci., 696, 54-62.

Smith et al. (1993) "FKBP54, a Novel FK506 Binding Protein in Avian
Progesterone Receptor Complexes and HeLa Extracts" J. Biol. Chem., 268,
24270-24273.

Rudert et al.(1994) "Apoptosis in L929 cells expressing a CD40/Fas chimeric
receptor: Dissociation of stimulatory from inhibory death signalling functions"
Biochem. Biophys. Res. Comm., 204, 1102.

Ke et al. (1994) "Crystal Structures of Cyclophilin A Complexed with

Cyclosporin A and
N-methyl-4-[(E)-2-Butenyl]-4,4-Dimethylthreonine
Cyclosporin
A" Structure, 2, 33-44.

Schultz et al. (1994) "Atomic Structure of the
Immunophilin FKBP13-FK506
Complex: Insights Into the Composite Binding Surface for
Calcineurin" J. Am.
Chem. Soc., 116,3129-3130.

Ikeda et al. (1994) "Structural Basis for
Peptidomimicry by a Natural
Product", J. Am. Chem. Soc., 116, 4143-4144.

Clipstone et al.(1994) "Calcineurin: Molecular analysis
of its interaction
with drug-immunophilin complexes and its role in the
regulation of NF-AT" J.
Cell. Biochem. Suppl. 0 (18B) 274, Abstract #1410.

Rosen M.K. (1993) "The molecular basis of
receptor-ligand-receptor
interactions: Studies of the immunophilin FKBP12", Abstract
of Doctoral Thesis.

Schreiber S.L. (1987) "Synthesis of materials with
physiological
properties" Abstract of NIH Grant R37GM38627.

Schreiber S.L. (1992) "Synthesis of materials with
physiological
properties" Abstract of NIH Grant R37GM38627.

Schreiber S.L. (1989) "Analysis of cyclosporin-receptor
interaction;
Synthesis of semi-peptide and non-peptide analogs of
cyclosporin A", Abstract
of NIH Grant P01GM406600001.

Crabtree G.R. (1987) "IL-2 receptor in the pathogenesis
of humanlymphoma"
Abstract of NIH Grant R01CA39612.

Crabtree G.R.(1988) "Pathways of T lymphocyte
activation" Abstract of NIH
Grant R01CA39612.

Crabtree G.R. (1991) "Pathways of T lymphocyte activation" Abstract of NIH Grant R01CA39612.

Schreiber et al.(1988) "Is There a Scaffolding Domain within the Structure of the Immunosuppressive Agent Cyclosporin A (CsA)? Studies of the Cyclophilin Binding Domain of CsA" Tetrahedron Lett., 29, 6577.

Schreiber et al. (1989) "Studies Relating to the Synthesis of the Immunosuppressive Agent FK506: Application of the Two Directional Chain Synthesis Strategy to the Pyranose Moiety" J. Org. Chem., 54, 9.

Schreiber et al. (1989) "Studies Relating to the Synthesis of the Immunosuppressive Agent FK506: Application of the Two Directional Chain Synthesis Strategy to the Pyranose Moiety" J. Org. Chem., 54, 15.

Schreiber et al. (1989) "Studies Relating to the Synthesis of the Immunosuppressive Agent FK506: Coupling of Fragments via a Stereoselective Trisubstituted Olefin Forming Reaction Sequence" J. Org. Chem., 54, 17.

Ragan et al. (1989) "Studies of the Immunosuppressive Agent FK506: Synthesis of an Advanced Intermediate" J. Org. Chem., 54, 4267.

Nakatsuka et al. (1990) "Total Syntheses of FK506 and an FKBP Probe Reagent, (C8, C9-13C2)-FK506" J. Am. Chem. Soc., , 112, 5583.

Somers et al. (1991) "Synthesis and Analysis of 506BD, a High Affinity Ligand to the Immunophilin, FKBP" J. Am. Chem. Soc., 113, 8045-8056.

Rosen et al. (1991) "Study of Receptor-Ligand Interations Through Receptor

Labeling and Isotope-Edited NMR" J. Org. Chem., 56, 6262.

Meyer et al. (1992) "Synthetic Investigations of Rapamycin. 1. Synthesis of a C10-C21 Fragment" J. Org. Chem., 57, 5058-5060.

Romo et al.(1992) "Synthetic Investigations of Rapamycin. 2. Synthesis of a C22-C42 Fragment" J. Org. Chem., 57, 5060-5063.

Romo et al. (1993) "Total Synthesis of Rapamycin Using an Evans-Tischenko Fragment Coupling" J. Am. Chem. Soc. , 115, 7906-7907.

Friedman and Weissman (1991) "Two Cytoplasmic Candidates for Immunophilin Action are Revealed by Affinity for a New Cyclophilin: One in the Presence and One in the Absence of CsA." Cell 66:799.

Liu et al. (1991) "Calcineurin Is a Common Target of Cyclophilin-Cyclosporin A and FKBP-FK506 Complexes." Cell 66:807.

Larson and Nuss (1993) "Cyclophilin-dependent stimulation of transcription by cyclosporin A." PNAS 90:148.

Edalji et al. (1992) "High-Level Expression of Recombinant Human FK-Binding Protein from a Fusion Precursor" J. Prot. Chem. 11:213.

Fischer et al. (1992) "Mip protein of Legionella pneumophila exhibits peptidyl-prolyl-cis/trans isomerase (Pplase) activity." Mol. Microbiol. 6:1375.

Sampson and Gotschlich (1992) "Neisseria meningitis encodes an FK506-inhibitable rotamase" PNAS 89:1164.

Price et al. (1991) "Human cyclophilin B: A second cyclophilin gene encodes a peptidyl-prolyl isomerase with a signal sequence." PNAS 88:1903.

Haendler et al. (1987) "Yeast cyclophilin: isolation and characterization

of the protein, cDNA and gene." EMBO J 6:947.

Zydowsky et al. (1992) "Overexpression, purification, and characterization
of yeast cyclophilins A and B." Protein Sci 1:961.

Liu (1993) "FK506 and cyclosporin, molecular probes for studying
intracellular signal transduction." Immunology Today 14:290.

Maki, et al. (1990) "Complementary DNA encoding the human T-cell
FK506-binding protein, a peptidylprolyl cis-trans isomerase distinct from
cyclophilin." PNAS USA 87:5440.

Standaert, et al. (1990) "Molecular cloning and overexpression of the human
FK506-binding protein FKBP" Nature 346:671.

Walsh, et al. (1992) "Cyclosporin A, the Cyclophilin Class of
Peptidylprolyl Isomerases, and Blockade of T Cell Signal Transduction" J Biol.
Chem. 267:13115.

Jin, et al. (1991) "Molecular cloning of a membrane-associated human FK506-
and rapamycin-binding protein, FKBP-13" PNAS USA 88:6677.

Hung and Schreiber (1992) "cDNA Cloning of a Human 25 kDa FK506 and
Rapamycin Binding Protein" Biochemical and Biophysical Research Communications
184:733.

Haendler, et al. (1989) "Yeast cyclophilin: isolation and characterization
of the protein, cDNA and gene" Gene. 83:39.

Bergsma et al. (1991) "The Cyclophilin Multigene Family of Peptidyl-Prolyl
Isomerases" J. Biol. Chem. 266:23204.

Tanida et al. (1991) Yeast Cyclophilin-related gene encodes a nonessential
second peptidyl-prolyl cis-trans isomerase.

Liu et al. (1990) "Cloning, expression, and purification of human cyclophilin in Escherichai coli and assessment of the catalytic role of cysteines by site-directed mutagenesis" PNAS 87:2304.

Zydowsky, et al. (1992) "Active site mutants of human cyclophilin A separate peptidyl-prolyl isomerase activity from cyclosporin A binding and calcineurin inhibition" Protein Science 1:1092.

Irving and Weiss (1991) "The Cytoplasmic Domain of the T Cell Receptor .zeta. Chain is Sufficient to Couple to Receptor-Associated Signal Transduction Pathways" Cell 64:891-901.

Kinet (1989) "Antibody-Cell Interactions: Fc Receptors" Cell 57:351-354.

Durand (1988) "Characterization of Antigen Receptor Response Elements within the Interleukin-2 Enhancer" Mol Cell Biol. 8:1715.

Orloff, et al. (1990) "Family of Disulphide-Linked Dimers Containing the .zeta. and .eta. Chains of the T-Cell Receptor and the .gamma. Chain of Fc Receptors" Nature 347:189-191.

Letourner and Klausner (1992) "Activation of T Cells by a Tyrosine Kinase Activation Domain in the Cytoplasmic Tail of CD3 .epsilon." Science 255:79-82.

Flanagan, et al. (1991) "Nuclear Association of a T-Cell Transcription Factor Blocked by FK-506 and Cyclosporin A" Nature 352:803-807.

Byrn, et al. (1990) "Biological Properties of a CD4 Immunoadhesin" Nature 344:667-670.

Lanier, et al. (1989) "Co-association of CD3.zeta. with a Receptor (CD16)

for IgG Fc on Human Natural Killer Cells" Nature 342:803-805.

Verweij et al. (1990) "Cell Type Specificity and Activation Requirements for NFAT-1 (Nuclear Factor of Activated T-Cells) Transcriptional Activity Determined by a New Method Using Transgenic Mice to Assay Transcriptional Activity of an Individual Nuclear Factor" J. Biol. Chem. 265:15788.

Clark, et al. (1992) "The B Cell Antigen Receptor Complex: Association of Ig-.alpha. and Ig-.beta. with Distinct Cytoplasmic Effectors" Science 258:123-126.

Shaw et al. (1988) "Identification of a Putative Regulator of Early T Cell Activation Genes" Science 241:202.

Weissman, et al. (1988) "Molecular Cloning and Chromosomal Localization of the Human T-Cell Receptor .zeta. Chain: Distinction from the Molecular CD3 Complex" PNAS USA 85:9709-9713.

Traber, et al. (1989) "Clyclosporins--New Analogues by Precursor Directed Biosynthesis" J. Antibiotics 42:591-597.

Patchett, et al. (1992) "Analogs of Cyclosporin A Modified at the D-ALA.sup.8 Position" J. Antibiotics 45:94-102.

Donald, et al. (1991) "C10 N-Acyl Modified FK-506: A Possible Hybrid Analogue of the Transition State of Petidyl-Prolyl Cis-Trans Isomeration" Tetrahedron Letters 31:1375-1378.

Emmel et al. (1989) "Cyclosporin A Specifically Inhibits Funciton of Nuclear Proteins Involved in T-Cell Activation"Science .

Eberle and Nuninger (1992) "Synthesis of the Main Metabolite (OL-17) of

Cyclosporin A" J Org Chem 57:2689-2691.

Nussbaumer, et al. (1992) "C9-Imino and C10-Amino Derivatives of Ascomycin (21-Ethyl-FK506)" Tetrahedron Letters 33:3845-3846.

Evans, et al. (1992) "Rhodium(I)- and Iridium(I)--Catalyzed Hydroboration Reactions: Scope and Synthetic Applications" J. Am. Chem. Soc. 114:6671-6679.

Evans, et al. (1992) "Mechanistic Study of the Rhodium(I)-Catalyzed Hydroboration Reaction" J. Am. Chem. Soc. 114:6679-6685.

Ghosh, et al. (1992) "N,N'-Disuccinimidyl Carbonate: A Useful Reagent for Alkoxycarbonylation of Amines" Tetrahedron Letters 33:2781-2784.

Zelle, et al. (1986) "A Systematic Degradation of Zincophorin: A Stereoselective Synthesis of the C.sub.17 -C.sub.25 Fragment" J. Org. Chem. 51:5032-5036.

Krishnamurthy (1981) "Lithium Tris[(3-ethyl-3-pentyl)oxy]aluminum Hydride. A New Remarkably Chemoselective Reagent for the Reduction of Aldehydes in the Presence of Ketones" J. Org. Chem. 46:4628-4629.

Fisher, et al. (1991) "On the Remarkable Propensity for Carbon-Carbon Bond Cleavage Reactions in the C.sub.8 -C.sub.10 Region of FK-506" J. Org. Chem. 56:2900-2097.

VanRheenen, et al. (1976) "An Improved Catalytic OsO.sub.4 Oxidation of the Olefins to Cis-1,2-Glycols Using Tertiary Amine Oxides as the Oxidant" Tetrahedron Letters 23:1973-1976.

Sistonen, et al. (1989) "Activation of the neu Tyrosine Kinase" J. Cell Biol. 109:1911-1919.

Peles, et al. (1992) "Regulated Coupling of the Neu Receptor to
Phosphatidylinositol" J. Biol. Chem. 267:12266-12274.

Wittbrodt, et al. (1992) "The Xmrk Receptor Tyrosine Kinase is Activated in
Xiphophorous Malignant Melanoma" EMBO J 11:4239-4246.

Bernard, et al. (1987) "High-affinity Interleukin-2 Binding by an Oncogenic
Hybrid Interleukin-2 Epidermal Growth Factor Receptor Molecule" PNAS USA
84:2125-2129.

Lee, et al. (1989) "HER2 Cytoplasmic Domain Generates Normal Mitogenic and
Transforming Signals in a Chimeric Receptor" EMBO J. 8:167-173.

Moe, et al. (1989) "Transmembrane Signaling by a Chimera of the Escherichia
coli Aspartate Receptor and the Human Insulin Receptor" PNAS USA 86:5683-5687.

Eiseman, et al. (1992) "Signal Transduction by the Cytoplasmic Domains of
Fc.epsilon.RI-.gamma. and TCR-J-.gamma. in Rat Basophilic Leukemia Cells".
Biol. Chem. 267:21027-21032.

Lammers, et al. (1989) "Differential Signaling Potential in Insulin- and
IGF-1-receptor Cytoplasmic Domains" EMBO J. 8:1369-1375.

Lehtola, et al. (1989) "Receptor Downregulation and DNA Synthesis are
Modulated by EGF and TPA in Cells Expressing an EGFR/neu Chimera" Growth
Factors 1:323-334. Abstract Only.

Lehvaslaiho, et al. (1989) "A Chimeric EGF-R-neu Proto-Oncogene Allows EGF
to Regulate neu Tyrosine Kinase and Cell Transformation" EMBO J. 8:159-166.

Margolis, et al. (1989) "All Autophosphorylation Sites of Epidermal Growth
Factor (EGF) Receptor and HER2/neu are Located in their

Carboxyl-Terminals
Tails" J. Biol. Chem. 264:10667-10671.

Riedel, et al. (1989) "Cytoplasmic Domains Determine Signal Specificity,
Cellular Routing Characteristics and Influence Ligand Binding of Epidermal
Growth Factor and Insulin Receptors" EMBO J. 8:2943-2954.

Roussel, et al. (1990) "Antibody-Induced Mitogenicity Mediated by a
Chimeric CD2-c-fms Receptor" Mol. Cell. Biol. 10:2407-2412.

Chan, et al. (1991) "The .zeta. Chain is associated with a Tyrosine Kinase
and upon T-Cell Antigen Receptor Stimulation Associates with ZAP-70, a 70-kDa
Tyrosine Phosphoprotein" PNAS USA 88:9166-9170.

Herbst, et al. (1991) "Substrate Phosphorylation Specificity of the Human
c-kit Receptor Tyrosine Kinase" J. Biol. Chem. 266(30):19908-19916.

Lev, et al. (1991) "A Specific Combination of Substrates is Involved in
Signal Transduction by the kit-Encoded Receptor" EMBO J. 10:647-654.

Ben-Levy, et al. (1992) "A oncogenic point mutation confers High Affinity
Ligand Binding to the neu Receptor" J. Biol. Chem. 267:17304-17313.

Bonnerot, et al. (1992) "Role of associated .gamma.-Chain in Tyrosine
Kinase Activtion via Murine FcRIII" EMBO J. 11(7):2747-2757.

Fields, S. and Song, O. (1989) "A Novel Genetic System to Detect
Protein-Protein Interactions" Nature 340:245-246.

Palmiter, et al. (1985) "Transgenic Mice" Cell 41:343-345.

Itoh, et al. (1993) "Effect of bcl-2 on Fas Antigen-Mediated Cell Death" J.

Immunol. 151:621-627.

Itoh and Nagata (1993) "A Novel Protein Domain Required for Apoptosis"
J.B.C. 268:10932.

Ptashne, et al. (1990) "Activators and Targets" Nature 346:329-331.

Watanabe-Fukunaga, et al. (1992) "Lymphoproliferation Disorder in Mice
Explained by Defects in Fas Antigen that Mediates Apoptosis" Nature
356:314-317.

Engel, et al. (1992) "High-Efficiency Expression and Solubization of
Functional T-Cell antigen Receptor Heterodimers" Science
256:1318-1321.

Gottschalk, et al. (1992) "The Carboxy Terminal 100 Amino Acid Portion of
the Insulin Receptor is Important for Isulin Signaling to Pyruvate
Dehydrogenase" Biochem & Biophys Res Comm 189: 906-911.

Howard, et al. (1992) "The CD3.zeta. Cytoplasmic Domain Mediates
CD2-Induced T Cell Activation" J. Exp. Med. 176:139-145.

Kruskal, et al. (1992) "Phagocytic Chimeric Receptors Require Both
Transmembrane and Cytoplasmic Domains from the Mannos Receptor" J. Exp. Med.
176:1673-1680.

Lee, et al. (1992) "Functional Dissection of Structural Domains in the
Receptor for Colony Stimulating Factor-1" J. Biol. Chem.
267:16472-16483.

Mares, et al. (1992) "A Chimera between Platelet-Derived Growth Factor
.beta.-receptor and Fibroblast Growth Factor Receptor-1 Stimulates Pancreatic
.beta.-DNA Synthesis in the Presence of PDGF-BB" Growth Factors 6:93-101.

Seedorf, et al. (1992) "Differential effects of carboxy-terminal sequence deletions on platelet-derived growth factor receptor signaling activities and interactions with cellular substrates" Mol. Cell. Biol. 12:4347-4356.

Venkitaraman, et al. (1992) "Interleukin 7 receptor functions by recruiting the tyrosine kinase p59.sup.tym through a segment of its cytoplasmic tail" PNAS USA 89:12083-12087.

Zhang, et al. (1992) "The insulin receptor-related receptor" J. Biol. Chem. 267:18320-18328.

Cantley, et al. (1991) "Oncogenes and signal transduction" Cell 64:281-302.

Yarden, et al. (1988) "Growth factor receptor tyrosine kinases" Ann. Rev. Biochem. 57:443-478.

Romeo, et al. (1991) "Cellular immunity to HIV activated by CD4 fused to T cell or Fc receptor polypeptides" Cell 64:1037-1046.

Levaslaiho, et al. (1990) "Regulation by EGF is maintained in an overexpressed chimeric EDGR/neu receptor tyrosine kinase" J. Cell. Biochem. 42:123-133.

Lev, et al. (1990) "Receptor functions and ligand-dependent transforming potential of a chimeric kit proto-oncogene" Mol. Cell Biol. 10(11):6064-6068.

Seedorf, et al. (1991) "Analysis of platelet-derived growth factor receptor domain function using a novel chimeric receptor approach" J. Biol. Chem. 266:12424-12431.

Fuh, et al. (1992) "Rational design of potent antagonists to the human growth hormone receptor." Science 256:1677-1680.

Lehtola, et al. (1992) "A chimeric EGFR/neu receptor in functional analysis
of the neu oncoprotein." Acta Oncologia 31(2):147-150.

Wennstrom, et al. (1992) "The platelet-derived growth factor beta-receptor
kinase insert confers specific signaling properties to a chimeric fibroblast
growth factor receptor." J. Biol. Chem. 267:13749-13756.

Reins, et al. (1993) "Anti-epidermal growth factor receptor monoclonal
antibodies affecting signal transduction." J. Cell. Biol. 51:236-248.

ART-UNIT: 166

PRIMARY-EXAMINER: Schwartzman; Robert A.

ABSTRACT:

We have developed a general procedure for the regulated (inducible)
dimerization or oligomerization of intracellular proteins and disclose methods
and materials for using that procedure to regulatably initiate cell-specific
apoptosis (programmed cell death) in genetically engineered cells.

18 Claims, 35 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 34

US-PAT-NO: 6187757
DOCUMENT-IDENTIFIER: US 6187757 B1

TITLE: Regulation of biological events using novel compounds

DATE-ISSUED: February 13, 2001

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Clackson; Timothy P.	Cambridge	MA	N/A	N/A
Gilman; Michael Z.	Newton	MA	N/A	N/A
Holt; Dennis A.	Royersford	PA	N/A	N/A
Keenan; Terence P.	Cambridge	MA	N/A	N/A
Rozamus; Leonard	Bedford	MA	N/A	N/A
Yang; Wu	Plainsboro	NJ	N/A	N/A

ASSIGNEE INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY	TYPE CODE
ARIAD Pharmaceuticals, Inc.	Cambridge	MA	N/A	N/A	02

APPL-NO: 09/ 012097

DATE FILED: January 22, 1998

PARENT-CASE:

This application is a continuation in part of U.S. Ser. No. 08/791,044, filed Jan. 28, 1997, which itself is a continuation in part of U.S. Ser. No. 08/481,941 (filed Jun. 7, 1995, now abandoned) and claims the benefit of U.S. Ser. No. 60/015,502 (filed Feb. 9, 1996) and is a continuation in part of

International Application No. PCT/US96/09948 (filed internationally Jun. 7, 1996).

INT-CL: [07] A61K031/70,C12N005/10

US-CL-ISSUED: 514/31;435/325 ;435/355 ;435/372 ;435/372.3 ;435/375

US-CL-CURRENT: 514/31; 435/325 ; 435/355 ; 435/372 ; 435/372.3 ; 435/375

FIELD-OF-SEARCH: 435/325; 435/355 ; 435/372 ; 435/372.3 ; 435/375 ; 514/31 ; 536/6.5

REF-CITED:

U.S. PATENT DOCUMENTS

PAT-NO	ISSUE-DATE	PATENTEE-NAME	US-CL
4797368	January 1989	Carter	N/A
5091389	February 1992	Ondeyka	N/A
5093338	March 1992	Byrne	N/A
5109112	April 1992	Siekierka	N/A
5116756	May 1992	Dumont	N/A
5139941	August 1992	Muzyczka	N/A
5140018	August 1992	Klein	N/A
5147877	September 1992	Goulet	N/A
5173414	December 1992	Lebkowski	N/A
5198421	March 1993	Chen	N/A
5200411	April 1993	Edmunds	N/A
5208241	May 1993	Ok	N/A
5210030	May 1993	Petuch	N/A
5221625	June 1993	Chen	N/A

5225403	July 1993		Treiber
N/A	N/A	N/A	
5247076	September 1993		Goulet
N/A	N/A	N/A	
5252479	October 1993		Srivastava
N/A	N/A	N/A	
5252610	October 1993		Caufield
N/A	N/A	N/A	
5252732	October 1993		Sinclair
N/A	N/A	N/A	
5258389	November 1993		Goulet
N/A	N/A	N/A	
5310901	May 1994		Parsons
N/A	N/A	N/A	
5310903	May 1994		Goulet
N/A	N/A	N/A	
5318895	June 1994		Kahn
N/A	N/A	N/A	
5324644	June 1994		Ruby
N/A	N/A	N/A	
5354678	October 1994		Lebkowski
N/A	N/A	N/A	
5362718	November 1994		Skotnicki
N/A	N/A	N/A	
5362735	November 1994		Luengo
N/A	N/A	N/A	
5373014	December 1994		Failli
N/A	N/A	N/A	
5378836	January 1995		Kao
N/A	N/A	N/A	
5387680	February 1995		Nelson
N/A	N/A	N/A	
5436146	July 1995		Shenk
N/A	N/A	N/A	
5457182	October 1995		Wiederrecht
N/A	N/A	N/A	
5457194	October 1995		Luly
N/A	N/A	N/A	
5484799	January 1996		Hochlowski
N/A	N/A	N/A	
5527907	June 1996		Or
N/A	N/A	N/A	
5534632	July 1996		Or
N/A	N/A	N/A	
5541189	July 1996		Luly
N/A	N/A	N/A	
5541193	July 1996		Kawai
N/A	N/A	N/A	

5559715	September 1996	Misheloff	
N/A	N/A	N/A	
5561137	October 1996	Or	
N/A	N/A	N/A	
5561228	October 1996	Or	
N/A	N/A	N/A	
5563172	October 1996	Wagner	
N/A	N/A	N/A	
5583139	December 1996	Or	
N/A	N/A	N/A	
5604234	February 1997	Or	
N/A	N/A	N/A	
5658776	August 1997	Flotte	
N/A	N/A	N/A	
9101616	November 1998	Clackson et al.	
N/A	N/A	N/A	

FOREIGN PATENT DOCUMENTS

FOREIGN-PAT-NO	PUBN-DATE	COUNTRY	US-CL
WO91/13889	September 1991	WO	
WO92/05179	April 1992	WO	
WO92/14737	September 1992	WO	
WO92/19595	November 1992	WO	
WO93/04680	March 1993	WO	
WO93/10122	May 1993	WO	
WO93/11130	June 1993	WO	
WO93/13663	July 1993	WO	
WO93/18043	September 1993	WO	
WO93/24641	December 1993	WO	
WO93/25533	December 1993	WO	
WO94/02136	February 1994	WO	
WO94/02137	February 1994	WO	
WO94/02485	February 1994	WO	
WO94/04540	March 1994	WO	
WO94/09010	April 1994	WO	
WO94/10843	May 1994	WO	
WO94/18317	August 1994	WO	
WO94/18207	August 1994	WO	
WO94/21644	September 1994	WO	
WO94/25022	November 1994	WO	
WO95/02684	January 1995	WO	
WO95/04521	February 1995	WO	
WO95/04738	February 1995	WO	
WO95/04060	February 1995	WO	
WO95/07468	March 1995	WO	
WO95/15328	June 1995	WO	
WO95/16691	June 1995	WO	

WO95/33052	December 1995	WO
WO96/00282	January 1996	WO
WO96/03430	February 1996	WO
WO96/13597	May 1996	WO
WO96/13598	May 1996	WO
WO96/20951	July 1996	WO
WO96/26285	August 1996	WO
WO96/35423	November 1996	WO
WO96/41807	December 1996	WO
WO96/41865	December 1996	WO
WO96/39530	December 1996	WO
WO97/02358	January 1997	WO
WO97/10502	March 1997	WO

OTHER PUBLICATIONS

Helliwell et al., Mol. Cell Biol. vol. 5: 105--118, 1994.

Korbutt et al., Transplantation Proc., 1995, vol. 27(6): 3212.

Ao et al., Transplantation Proc. , 1995, vol. 27(6): 3349-3350.

Belshaw, et al., Proc. Natl. Acad. Sci. USA, vol. 93: 4604-4607, 1996.

Borelli, et al., Porc. Natl. Acad. Sci. USA, 1988, vol. 85: 7572-7576.

Breitman, et al., Science, 1987, vol. 238: 1563-1565.

Breitman et al., Mol. Cell. Biol., 1990, vol. 10: 474-479.

Brown, et al., Nature, vol. 369: 756-758, 1994.

Chen, et al., PNAS USA, vol. 92: 4947-4951, 1995.

Chiu et al., PNAS USA, vol. 91: 12574-12578, 1994.

Cunningham et al., Science, 1989, vol. 244: 1081-1085.

Das et al., Nature, 1995, vol. 374: 657-660.

Dennis et al, J. Biol. Chem, 1994, vol. 269: 22129-22136.

Ferry et al., Proc. Natl. Acad. Sci. USA, 1991, vol. 88: 8377-8381.

Fields et al., Nature, 1989, vol. 340: 245-246.

Flotte et al., J. Biol. Chem, 1993, vol. 268: 3781-3790.

Grinfeld, et al., Tett Letters, vol. 35 (7): 6835-6838, 1994.

Heyman et al., Proc. Natl. Acad. Sci. USA, 1989, vol. 86: 2698-2702.

Hiebert et al., Proc. Natl. Acad. Sci, USA, 1989, vol. 86: 3594-3598.

Ho, et al., Nature, vol. 382: 822-826, 1996.

Holsinger, et al., Proc. Natl. Acad. Sci. USA, vol. 92: 9810-9814, 1995.

Hu, Structure, 1995, vol. 3: 431-433.

Hu et al., Science, 1990, vol. 250: 1400-1403.

Kaneda et al., Science, 1989, vol. 243: 375-378.

Kay, Biochem. J., vol. 314: 361-385, 1996.

Kordower et al., PNAS USA, 1994, vol. 91(23): 10898-902.

Kunz et al., Cell, vol. 73: 585-596, 1993.

Lakey et al., Transplantation Proc., 1995, vol. 27(6): 3266.

Liberies et al., 1997, Proc. Natl. Acad. Sci. USA, vol. 94: 7825-7830.

Luengo et al., 1995, J. Org. Chem., 59, 6512.

Luengo et al., 1995, Chem & Biol, vol. 2(7): 471-481.

Luo, et al., Nature, vol. 383: 181-185, 1996.

Muller et al., MCB, 1991, vol. 11: 1785-1792.

Palmiter, et al., Cell, 1987, vol. 50: 435-443.

Pomeranz, et al., Science, vol. 267: 93-96, 1995.

Pruschy, et al., Chemistry & Biology, vol. 1 (3): 163-172, 1994.

Rajotte et al., Transplantation Proc., 1995, vol. 27(6): 3389.

Riddell, et al., Nature Med., 1996, vol. 2: 216-223.

Rivera, et al., Nature Medicine, vol. 2: 1028-1032, 1996.

Siekieka et al., Nature, 1989, vol. 341: 755-757.

Smith et al., J. Am. Chem. Soc., 1997, vol. 119: 962-973.

Spencer et al., Proc. Natl. Acad. Sci. USA, vol. 92: 9805-9809, 1995.

Spencer, et al., "Controlling Signal Transduction with Synthetic Ligands", Science, 262:1019-1024, 1993.

Spencer, et al., Current Biology, vol. 6: 839-847, 1996.

Staendart, et al., Nature, vol. 346: 671-674, 1990.

Stemmer, Nature, 1994, vol. 370: 389-391.

Thomas et al, Cell, 1987, vol. 51: 503-512.

Uchiyama, et al., "Synthesis of Hybrid Type of Anti-HIV Drugs", Peptide Chemistry 1993; 31(1):89-92, 1994.

Van Duyne et al., J. Amer. Chem. Soc., 1991, vol. 113: 7433-7434.

Winn et al., PNAS USA, 1994, vol. 91(6): 2324-2328.

U.S. application No. 09/101,616, Clackson et al., filed

Nov. 2, 1998.

ART-UNIT: 166

PRIMARY-EXAMINER: Schwartzman; Robert A.

ABSTRACT:

Materials and methods are disclosed for regulation of biological events such as target gene transcription and growth, proliferation or differentiation of engineered cells.

54 Claims, 6 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 5

US-PAT-NO: 6077947
DOCUMENT-IDENTIFIER: US 6077947 A

TITLE: DNA encoding an intracellular chimeric receptor comprising Janus kinase

DATE-ISSUED: June 20, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Capon; Daniel J.	Hillsborough	CA	N/A	N/A
Tian; Huan	Cupertino	CA	N/A	N/A
Smith; Douglas H.	Foster City	CA	N/A	N/A
Winslow; Genine A.	Hayward	CA	N/A	N/A
Siekevitz; Miriam	New York	NY	N/A	N/A

ASSIGNEE INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY	TYPE CODE
Cell Genesys, Inc.	Foster City	CA	N/A	N/A	02

APPL-NO: 08/ 485598

DATE FILED: June 7, 1995

PARENT-CASE:

This application is a continuation application of application Ser. No. 08/382,846, filed Feb. 2, 1995, which is now abandoned.

INT-CL: [07] C12N015/62,C12N015/52 ,C12N015/63 ,C12N005/10

US-CL-ISSUED: 536/23.4;435/69.7 ;435/320.1 ;435/325 ;530/350 ;530/387.3

US-CL-CURRENT: 536/23.4; 435/320.1 ; 435/325 ; 435/69.7 ;

530/350 ; 530/387.3

FIELD-OF-SEARCH: 536/23.4; 435/69.7 ; 435/240.2 ; 435/320.1 ; 435/325
; 530/387.3 ; 530/350

REF-CITED:

U.S. PATENT DOCUMENTS

PAT-NO	ISSUE-DATE	PATENTEE-NAME	US-CL
5359046	October 1994	Capon et al.	536/23.4
	N/A	N/A	
5470730	November 1995	Greenberg et al.	435/172.3
	N/A	N/A	
5504000	April 1996	Littman et al.	435/194
	N/A	N/A	

FOREIGN PATENT DOCUMENTS

FOREIGN-PAT-NO	PUBN-DATE	COUNTRY	US-CL
0340793	August 1989	EP	
WO 9319163	September 1993	WO	
WO 94/18317	August 1994	WO	
WO 9429438	December 1994	WO	

OTHER PUBLICATIONS

Heinzel et al., Use of Simian Virus 40 replication to amplify Epstein-Barr virus shuttle vectors in human cells, J. Virol. 62:3738-3746 (1988).

Kishimoto et al., Cytokine Signal Transduction, Cell 76:253-262 (1994).

Morgan and Anderson, Human Gene Therapy, Ann. Rev. Biochem. 62:191-217 (1993).

Mulligan, The Basic Science of Gene Therapy, Science 360:926-930 (1993).

Niehuis et al., Gene Transfer into Hematopoietic Stem Cells, Cancer 67:2700-2704 (1991).

Orkin et al., Report and Recommendations of the Panel to Assess the NIH

Investment in Research on Gene Therapy (1995).

Paul, Tumor Immunology, Fundamental Immunol., Chap. 34, pp. 923-955 (1989).

Riddell et al., Genetically Modified T-Cell Clones as a Treatment for Human
Viral Diseases, Soc. Biol. Therapy, (Meeting Abstract), p. 50 (1993).

Spencer et al., Controlling Signal Transduction with Synthetic Ligands,
Science 262:1019-1024 (1993).

Stancovski et al., Targeting of T Lymphocytes to Neu/Her-2-expressing Cells
using chimeric Single Chain Fv Receptors, J. Immunol. 151:6577-6582 (1993).

Travis, Making Molecular matches in the Cell, Science 262:989 (1993).

Weatherall, Scope and Limitations of Gene Therapy, British med. Bull.
51:1-11 (1995).

Mangelsdorf et al. (1995) Cell 83:835-839, 1995.

Watson et al. (1994) The G-Protein Linked Receptor FactsBook, Academic
Press Limited, San Diego, CA, pp. X-XL, 3-6, 1994.

Barclay et al. (1993) The Leucocyte Antigen FactsBook, Academic Press
Limited, San Diego, CA, pp. 2-7, 22-25, 1993,

Bowie et al. (1990) Science.

Nakamura et al. Nature 369 : 330-333 (1994).

Miyazaki et al. Science 266 : 1045-1047 (1994).

Sakai et al. J. Biol. Chem. 270:18420-18427.

ART-UNIT: 166

PRIMARY-EXAMINER: Feisee; Lila

ASSISTANT-EXAMINER: Pak; Michael

ABSTRACT:

The present invention is directed to novel chimeric proliferation receptor proteins and DNA sequences encoding these proteins where the chimeric proteins are characterized in three general categories. In one category, the novel chimeric proteins comprise at least three domains, namely, an extracellular inducer-responsive clustering domain capable of binding an extracellular inducer that transmits a signal to a proliferation signaling domain, a transmembrane domain and a proliferation signaling domain that signals a host cell to divide. In the second category, the novel chimeric proteins comprise at least two domains, namely, an intracellular inducer-responsive clustering domain capable of binding an intracellular inducer and a proliferation signaling domain that signals the cell to divide. In yet a third category, a novel hybrid chimeric protein receptor is contemplated that contains an intracellular or extracellular inducer domain, a transmembrane domain, a proliferation signaling domain and an effector signaling domain in a single chain molecule. Whether the binding domain is intracellular or extracellular, the binding of inducer to these novel chimeric receptor proteins induces the clustering of the binding domains to each other and further signals the cell to proliferate, and optionally, signal an effector function. The present invention further relates to expression vectors containing the nucleic acids encoding the novel chimeric receptors, cells expressing the novel chimeric receptors and therapeutic methods of using cells expressing these novel receptors for the treatment of cancer, infectious disease and autoimmune

diseases, for example.

14 Claims, 4 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 6

US-PAT-NO: 6054436
DOCUMENT-IDENTIFIER: US 6054436 A

TITLE: Regulated apoptosis

DATE-ISSUED: April 25, 2000

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Crabtree; Gerald R.	Woodside	CA	N/A	N/A
Schreiber; Stuart L.	Cambridge	MA	N/A	N/A
Spencer; David M.	Los Altos	CA	N/A	N/A
Wandless; Thomas J.	Cambridge	MA	N/A	N/A
Belshaw; Peter	Cambridge	MA	N/A	N/A

ASSIGNEE INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY	TYPE CODE
Board of Trustees of Leland S. Stanford Jr. Univ.	Stanford	CA	N/A	N/A	02
President & Fellows of Harvard College	Cambridge	MA	N/A	N/A	02

APPL-NO: 09/ 087811

DATE FILED: May 29, 1998

PARENT-CASE:

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a continuation of U.S. Ser. No. 08/292,597, filed Aug. 18, 1994, U.S. Pat. No. 5,834,266, which is a continuation-in-part of Ser. No. 08/179,143 filed Jan. 7, 1994, abandoned, which is a continuation-in-part of Ser. No.

08/093,499 filed Jul. 16, 1993, abandoned, this case is also a continuation-in-part of Ser. No. 08/196,043 filed Feb. 14, 1994, abandoned, which is a continuation-in-part of Ser. No. 08/179,748 filed Jan. 7, 1994, abandoned, which is a continuation-in-part of Ser. No. 08/092,977 filed Jul. 16, 1993, abandoned, which is a continuation-in-part of Ser. No. 08/017,931 filed Feb. 12, 1993, abandoned. The contents of each of these applications is hereby incorporated by referenced into the present disclosure. The full contents of related cases PCT/US94/01617, PCT/US94/01660 and PCT/US94/08008 are also incorporated by reference into the present disclosure.

INT-CL: [07] A61K031/70,A61K038/12 ,A61K048/00 ,C12N005/10

US-CL-ISSUED: 514/31;424/93.21 ;435/325 ;435/372.3 ;514/9

US-CL-CURRENT: 514/31; 424/93.21 ; 435/325 ; 435/372.3 ; 514/9

FIELD-OF-SEARCH: 424/93.2; 424/93.21 ; 435/325 ; 435/372.3 ; 435/455 ; 514/9 ; 514/31

REF-CITED:

U.S. PATENT DOCUMENTS

PAT-NO	ISSUE-DATE	PATENTEE-NAME	US-CL
5171671	December 1992	Evans et al.	435/69.1
N/A	N/A	N/A	

FOREIGN PATENT DOCUMENTS

FOREIGN-PAT-NO	PUBN-DATE	COUNTRY	US-CL
0 594 847 A1	April 1994	EP	
WO 92/01052	January 1992	WO	
WO 93/23550	November 1993	WO	
WO 93/25533	December 1993	WO	

OTHER PUBLICATIONS

Harding et al. (1989) "A Receptor for the Immunosuppressant FK506 is a cis-trans Peptidyl-Prolyl Isomerase" Nature 341, 758.

Schreiber et al. (1991) "Immunophilin-Ligand Complexes as Probes of Intracellular Signaling Pathways" Transplantation Proceedings, 23, 2839.

Schreiber et al. (1992) "Molecular Recognition of Immunophilins and Immunophilin-Ligand Complexes" Tetrahedron 148: 2545-2558.

Schreiber et al. (1991) "Protein Overproduction for Organic Chemists" Tetrahedron, 47, 2543-2562.

Rosen et al. (1992)"Natural Products as Probes of Cellular Function: Studies of Immunophilins" Angew. Chemie, Int. Ed. Eng., 31,384-400.

Bram et al. (1993) "Identification of the Immunophilins Capable of Mediating Inhibition of Signal Transduction by Cyclosphorin A and FK506: Roles of Calcineurin Binding and Cellular Location" Mol. Cell Biol., 13, 4760-4769.

Selvakumaran et al. (1993) "Myeloblastic leukemia cells conditionally blocked by Myc-estrogen receptor chimeric transgenes for terminal differentiation coupled to growth arrest and apoptosis" Blood, 81:2257.

Wandless T.J. (1993) "Turning genes on and off using FKBP and FK506" Doctoral Thesis.

Standaert R.F. (1992) "Biochemical and structural studies of the FK506- and rapamycin-binding proteins (FKBPs)", Abstract of Doctoral Thesis.

Bierer et al. (1990) "Mechanisms of Immunosuppression by FK506: Preservation of T Cell Transmembrane Signal Transduction"

Transplantation, 49,
1168.

Rosen et al. (1990) "Inhibition of FKBP Rotamase Activity by
Immunosuppressant FK506: A Twisted Amide Surrogate"
Science, 248, 863.

Bierer et al. (1990) "Two Distinct Signal Transmission Pathways in T
Lymphocytes are Inhibited by Complexes Formed Between an Immunophilin and
Either FK506 or Rapamycin" PNAS U.S.A., 87, 9231.

Albers et al. (1990) "Substrate Specificity for the Human Rotamase FKBP: A
View of FK506 and Rapamycin as Leucine (twisted
amide)-Proline Mimics" J. Org.
Chem., 55, 4984.

Bierer et al. (1990) "Probing Immunosuppressant Action with a Nonnatural
Immunophilin Ligand" Science, 250, 556.

Schreiber S.L. (1991) "Chemistry and Biology of the Immunophilins and Their
Immunosuppressive Ligands" Science, 251, 283.

Fretz et al. (1991) "Rapamycin and FK506 Binding Proteins (Immunophilins)"
J. Am. Chem. Soc., 113, 1409.

Beirer et al. (1991) "The Effect of the Immunosuppressant FK506 on
Alternate Pathways of T Cell Activation" Eur. J. Immunol., 21, 439-445.

Wandless et al.(1991) "FK506 and Rapamycin Binding to FKBP: Common Elements
Involved in Immunophilin-Ligand Complexation" J. Am. Chem. Soc., 113,
2339-2341.

Lane et al. (1991) "Complete Amino Acid Sequence of the FK506 and Rapamycin
Binding Protein, FKBP, Isolated from Calf Thymus" J. Prot. Chem., 10, 151-160.

Hultsch et al. (1991) "Inhibition of IgE Receptor-Mediated Exocytosis from Rat Basophilic Leukemia Cells by FK506 is Reversed by Rapamycin: Evidence for Common Signaling Pathways in Mast Cells and T Lymphocytes" FASEB J., 5, A1008 (3705).

Rosen et al. (1991) "Proton and Nitrogen Sequential Assignments and Secondary Structure Determination of the Human FK506 and Rapamycin Binding Protein" Biochemistry, 30, 4774-4789.

Michnick et al. (1991) "Solution Structure of FKBP, a Rotamase Enzyme and Receptor for FK506 and Rapamycin" Science 252, 836-839.

Van Duyne et al. (1991) "Atomic Structure of FKBP-FK506, an Immunophilin-Immunosuppressant Complex" Science, 252, 839-842.

Albers et al. (1991) "FKBP, Thought to Be Identical to PKCI-2, Does Not Inhibit Protein Kinase C" BioMed. Chem. Lett., 1, 205-210.

Albers et al. (1991)"The Relationship of FKBP to PKCI-2" Nature, 351, 527.

Hultsch et al. (1991) "Immunophilin Ligands Demonstrate Common Features of Signal Transduction Leading to Exocytosis or Transcription" PNAS USA., 88, 6229-6233.

Van Duyne et al. (1991) "Atomic Structure of the Rapamycin human immunophilin FKBP-12 complex" J. Am. Chem. Soc., 113, 7433.

Ullman et al. (1991) "Site of action of cyclosporine and FK506 in the pathways of communication between the T-lymhocyte antigen receptor and the early activation genes" Transplant. Proceed., 23, 2845.

Galat et al. (1992) "Rapamycin-Selective 25 kDa Immunophilin" Biochemistry,

31, 2427-2434.

Schreiber et al. (1992) "The Mechanism of Action of Cyclosporin A and FK506" Immunology Today, 13, 136-142.

Liu et al. (1992) "Inhibition of T Cell Signaling by Immunophilin-Ligand Complexes Correlates With Loss of Calcineurin Phosphatase Activity" Biochemistry, 31, 3896-3901.

Francavilla et al. (1992) "Inhibition of Liver, Kidney, and Intestine Regeneration by Rapamycin" Transplantation, 53, 496-498.

Tai et al. (1992) "Association of a 59-Kilodalton Immunophilin with the Glucocorticoid Receptor Complex" Science, 256, 1315-1318.

Schreiber S.L.(1992) "Immunophilin-Sensitive Phosphatase Action in Cell Signaling Pathways" Cell, 70, 365-368.

Kaye et al. (1992) "Effects of Cyclosporin A and FK506 on Fce Receptor type I-Initiated Increases in Cytokine mRNA in Mouse Bone Marrow-Derived Progenito Mast Cells: Resistance to FK506 is Associated with a Deficiency in FKBP12", PNAS USA, 89, 8542-8546.

DiLella et al.(1992) "Chromosomal Band Assignments of the Genes Encoding Human FKBP12 and FKBP13" Biochem. Biophys. Res. Commun., 189, 819-823.

Chung et al. (1992) "Rapamycin-FKBP specifically blocks growth-dependent activation of and signalling by the 70 kd S6 protein kinases" Cell, 69, 1227.

Flanagan et al. (1992) "Intracellular signal transmission: a novel role for the prolyl isomerases" J. Cell. Biochem. Suppl. 0 (16 Part A), 61, Abstract #B005.

Kao et al. (1992) "Nuclear target of cyclosporin A and FK506 action is specifically bound by a heterodimeric protein comprising molecular weights 90K and 45K" J. Cell. Biochem. Suppl. 0 (16 Part B), 239. Abstract #H523.

Flanagan et al. (1992) "Nuclear association of a transcription factor essential for T cell activation by cyclosporin A and FK506" J. Cell. Biochem. Suppl. 0 (16 Part B), 237, Abstract #H514.

Serafini et al. (1992) "Selection and characterization of mutants in a signal transduction/transmission pathway" J. Cell. Biochem. Suppl. 0 (6 Part A) 89, Abstract #B234.

Yang et al. (1993) "A Composite FKBP12-FK506 Surface That Contacts Calcineurin" J. Am. Chem. Soc., 115, 819-820.

Rosen et al. (1993) "Activation of an Inactive Immunophilin by Mutagenesis" J. Am. Chem. Soc., 115, 821-822.

Van Duyne et al. (1993) "Atomic Structures of the Human Immnophilin FKBP12 Complexes with FK506- and Rapamycin" J. Mol. Biol., 229, 105-124.

Tai et al. (1993) "P59 (FK506 Binding Protein 59) Interaction with Heat Shock Proteins is Highly Conserved and May Involve Proteins Other Than Steroid Receptors" Biochemistry, 32, 8842-8847.

Alberg et al. (1993) "Structure-Based Design of a Cyclophilin-Calcineurin Bridging Ligand" Science, 262, 248-250.

Andrus et al. (1993) "Structure-Based Design of an Acyclic Ligand That Bridges FKBP12 and Calcineurin" J. Am. Chem. Soc., 115, 10420-10421.

Albers et al. (1993) "An FKBP-Rapamycin Sensitive,

Cyclin-Dependent Kinase
Activity That Correlates With the FKBP Rapamycin-Induced G1
Arrest Point in
MG-63 Cells" Annals of N. Y. Acad. Sci., 696, 54-62.

Smith et al. (1993) "FKBP54, a Novel FK506 Binding
Protein in Avian
Progesterone Receptor Complexes and HeLa Extracts" J. Biol.
Chem., 268,
24270-24273.

Rudert et al. (1994) "Apoptosis in L929 cells
expressing a CD40/Fas
chimeric receptor: Dissociation of stimulatory from
inhibory death signaling
functions" Biochem. Biophys. Res. Comm., 204, 1102.

Ke et al. (1994) "Crystal Structures of Cyclophilin A
Complexed with
Cyclosporin A and
N-methyl-4-[(E)-2-Butenyl]-4,4-Dimethylthreonine
Cyclosporin
A" Structure, 2, 33-44.

Schultz et al. (1994) "Atomic Structure of the
Immunophilin FKBP13-FK506
Complex: Insights Into the Composite Binding Surface for
Calcineurin" J. Am.
Chem. Soc., 116,3129-3130.

Ikeda et al. (1994) "Structural Basis for
Peptidomimicry by a Natural
Product" , J. Am. Chem. Soc., 116, 4143-4144.

Clipstone et al. (1994) "Calcineurin: Molecular
analysis of its interaction
with drug-immunophilin complexes and its role in the
regulation of NF-AT" J.
Cell. Biochem. Suppl. 0 (18B) 274, Abstract #1410.

Rosen M.K. (1993) "The molecular basis of
receptor-ligand-receptor
interactions: Studies of the immunophilin FKBP12", Abstract
of Doctoral Thesis.

Schreiber S.L. (1987) "Synthesis of materials with
physiological
properties" Abstract of NIH Grant R37GM38627.

Schreiber S.L. (1992) "Synthesis of materials with physiological properties" Abstract of NIH Grant R37GM38627.

Schreiber S.L. (1989) "Analysis of cyclosporin-receptor interaction; Synthesis of semi-peptide and non-peptide analogs of cyclosporin A", Abstract of NIH Grant P01GM406600001.

Crabtree G.R. (1987) "IL-2 receptor in the pathogenesis of humanlymphoma" Abstract of NIH Grant R01CA39612.

Crabtree G.R. (1988) "Pathways of T lymphocyte activation" Abstract of NIH Grant R01CA39612.

Crabtree G.R. (1991) "Pathways of T lymphocyte activation" Abstract of NIH Grant R01CA39612.

Schreiber et al.(1988) "Is There a Scaffolding Domain within the Structure of the Immunosuppressive Agent Cyclosporin A (CsA)? Studies of the Cyclophilin Binding Domain of CsA" Tetrahedron Lett., 29, 6577.

Schreiber et al. (1989) "Studies Relating to the Synthesis of the Immunosuppressive Agent FK506: Application of the Two Directional Chain Synthesis Strategy to the Pyranose Moiety" J. Org. Chem., 54, 9.

Schreiber et al. (1989) "Studies Relating to the Synthesis of the Immunosuppressive Agent FK506: Application of the Two Directional Chain Synthesis Strategy to the Pyranose Moiety" J. Org. Chem., 54, 15.

Schreiber et al. (1989) "Studies Relating to the Synthesis of the Immunosuppressive Agent FK506: Coupling of Fragments via a Stereoselective Trisubstituted Olefin Forming Reaction Sequence" J. Org.

Chem., 54, 17.

Ragan et al. (1989) "Studies of the Immunosuppressive Agent FK506:
Synthesis of an Advanced Intermediate" J. Org. Chem., 54, 4267.

Nakatsuka et al. (1990) "Total Syntheses of FK506 and an FKBP Probe
Reagent, (C8, C9-13C2)-FK506" J. Am. Chem. Soc., , 112, 5583.

Somers et al. (1991) "Synthesis and Analysis of 506BD, a High Affinity
Ligand to the Immunophilin, FKBP" J. Am. Chem. Soc., 8045-8056.

Rosen et al. (1991) "Study of Receptor-Ligand Interactions Through Receptor
Labeling and Isotope-Edited NMR" J. Org. Chem., 56, 6262.

Meyer et al. (1992) "Synthetic Investigations of Rapamycin. 1. Synthesis of
a C10-C21 Fragment" J. Org. Chem., 57, 5058-5060.

Romo et al. (1992) "Synthetic Investigations of Rapamycin. 2. Synthesis of
a C22-C42 Fragment" J. Org. Chem., 57, 5060-5063.

Romo et al. (1993) "Total Synthesis of Rapamycin Using an Evans-Tischenko
Fragment Coupling" J. Am. Chem. Soc., 115, 7906-7907.

Irving and Weiss (1991) "The Cytoplasmic Domain of the T Cell Receptor
.zeta. Chain is Sufficient to Couple to Receptor Associated Signal Transduction
Pathways" Cel 164;891-901.

Kinet (1989) "Antibody-Cell Interactions: Fc Receptors"Cell 57:351-354.

Durand (1988) "Characterization of Antigens Receptor Response Elements
within the Interleukins-2 Enchaner" Mol Cell Biol. 8:1715.

Orloff, et al. (1990) "Family of Disulphide-Linked Dimers Containing the

.zeta. and .eta. Chains of the T-Cell Receptor and the .gamma. Chain of Fc
Receptors" Nature 347:189-191.

Letourner and Klausner (1992) "Activation of T Cells by a Tyrosine Kinase
Activation Domain in the Cytoplasmic Tail of CD3 .epsilon." Science 255:79-82.

Flanagan, et al. (1991) "Nuclear Association of a T-Cell Transcription
Factor Blocked by FK-506 and Cyclosporin A" Nature 352:803-807.

Byrn, et al. (1990) "Biological Properties of a CD4 Immunoadhesin" Nature
344:667-670.

Lanier, et al. (1989) "Co-association of CD3.zeta. with a Receptor (CD16)
for IgG Fc on Human Nature Killer Cells" Nature 342:803-805.

Mattila, et al. (1990) "The Actions of Cyclosproin A and FK506 Suggest A
Novel Step in the Activation of T Lymphocytes" EMBO J 9(13):4425-4433.

Verweij et al. (1990) "Cell Type Specificity and Activation Requirements
for NFAT-1 (Nuclear Factor of Activated T-Cells) Transcriptional Activity
Determined by a New Method Using Transgenic Mice to Assay Transcriptional
Activity of an Individual Nuclear Factor" J. Biol. Chem. 265:15788.

Clark, et al. (1992) "The B Cell Antigen Receptor Complex: Association of
lg-.alpha. and lg-.beta. with Distinct Cytoplasmic Effectors", Science
258;123-126.

Weissman, et al. (1988) "Molecular Cloning and Chromosomal Localization of
the Human T-Cell Receptor.zeta. Chain: Distinction from the Molecular CD3
Complex" PNAS USA 85:9709-9713.

Traber, et al. (1989) "Cyclosporins--New Analogues by Precusor Directed Biosynthesis" J Antibiotics 42;591-597.

Patchett, et al. (1992) "Analogs of Cyclosporin A Modified at the D-ALA.sup.8 Position" J Antibiotics 45:94-102.

Donald, et al. (1991) "C10 N-Acyl Modified FK-506: A Possible Hybrid Analogue of the Transition State of Petidyl-Prolyl Cis-Trans Isomerization" Tetrahedron Letters 31:1375-1378.

Emmel et al. (1989) "Cyclosporin A Specifically Inhibits Funciton of Nuclear Proteins Involved in T-Cell Activation" Science.

Eberle and Nuninger (1992) "Synthesis of the Main Metabolite (OL-17) of Cyclosporin A" J Org Chem 57:2689-2691.

Nussbaumer, et al. (1992) "C9-Imino and C10-Amino Derivatives of Ascomycin (21-Ethyl-FK506)" Tetrahedron Letters 33:3845-3846.

Evans, et al. (1992) "Rhodium(l)- and Iridium(l)--Catalyzed Hydroboration Reactions: Scope and Synthetic Applications" J. Am. Chem. Soc. 114:6671-6679.

Evans, et al. (1992) "Mechanistic Study of the Rhodium(l)-Catalyzed Hydroboration Reaction" J. Am. Chem. Soc. 114:6679-6685.

Ghosh, et al. (1992) "N,N'-Dissuccinimidyl Carbonate: A Useful Reagent for Alkoxycarbonylation of Amines" Tetrahedron Letters 33:2781-2784.

Zelle, et al. (1986) "A Systematic Degradation of Zincophorin: A Stereoselective Synthesis of the C.sub.17 -C.sub.25 Fragment" J. Org. Chem. 51:5032-5036.

Krishnamurthy (1981) "Lithium

Tris[(3-ethyl-3-pentyl)oxy]aluminum Hydride.
A New Remarkably Chemoselective Reagent for the Reduction of Aldehydes in the
Presence of Ketones" J. Org. Chem. 46:4628-4629.

Fisher, et al. (1991) "On the Remarkable Propensity for Carbon-Carbon Bond
Cleavage Reactions in the C.sub.8 -C.sub.10 Region of FK-506" J. Org. Chem.
56:2900-2907.

VanRheenen, et al. (1976) "An Improved Catalytic OsO.sub.4 Oxidation of the
Olefins to Cis-1,2-Glycols Using Tertiary Amine Oxides as the Oxidant"
Tetrahedron Letters 23:1973-1976.

Sistonen, et al. (1989) "Activation of the neu Tyrosine Kinase" J. Cell.
Biol. 109:1911-1919.

Peles, et al. (1992) "Regulated Coupling of the Neu Receptor to
Phosphatidylinositol" J. Biol. Chem. 267:12266-12274.

Wittbrodt, et al. (1992) "The Xmrk Receptor Tyrosine Kinase is Activated in
Xiphophorous Malignant Melanoma"EMBO J 11:4239-4246.

Bernard, et al. (1987) "High-affinity Interleukin-2 Binding by an Oncogenic
Hybrid Interleukin-2 Epidermal Growth Factor Receptor Molecule" PNAS USA
84:2125-2129.

Lee, et al. (1989) "HER2 Cytoplasmic Domain Generates Normal Mitogenic and
Transforming Signals in a Chimeric Receptor" EMBO J. 8:167-173.

Moe, et al. (1989) "Transmembrane Signaling by a Chimera of the Escherichia
coli Aspartate Receptor and the Human Insulin Receptor" PNAS USA 86:5683-5687.

Eiseman, et al. (1992) "Signal Transduction by the Cytoplasmic Domains of
Fc.epsilon.RI-.gamma. and TCR-J-.gamma. in Rat Basophilic

Leukemia Cells".
Biol. Chem. 267:21027-21032.

Lammers, et al. (1989) "Differential Signaling Potential in Insulin- and IGF-1-receptor Cytoplasmic Domains" EMBO J. 8:1369-1375.

Lehtola, et al. (1989) "Receptor Downregulation and DNA Synthesis are Modulated by EGF and TPA in Cells Expressing an EGFR/neu Chimera" Growth Factors 1:323-334 Abstract only.

Lehvaslaiho, et al. (1989) "A Chimeric EGF-R-neu Proto-Oncogene Allows EGF to Regulate neu Tyrosine Kinase and Cell Transformation" EMBO J. 8:159-166.

Margolis, et al. (1989) "All Autophosphorylation Sites of Epidermal Growth Factor (EGF) Receptor and HER2/neu are Located in their Carboxyl-Terminals Tails" J. Biol. Chem. 264:10667-10671.

Reidel, et al. (1989) "Cytoplasmic Domains Determine Signal Specificty, Cellular Routing Characteristics and Influence Ligand Binding of Epidermal Growth Factor and Insulin Receptors" EMBO J. 8:2943-2954.

Roussel, et al. (1990) "Antibody-Induced Mitogenicity Mediated by a Chimeric CD2-c-fms Receptor" Mol. Cell. Biol. 10:2407-2412.

Chan, et al. (1991) "The .zeta. Chain is associated with a Tyrosine Kinase and upon T-Cell Antigen Receptor Stimulation Associates with ZAP-70, a 70-kDa Tyrosine Phosphoprotein" PNAS USA 88:9166-9170.

Herbst, et al. (1991) "Substrate Phosphorylation Specificity of the Human c-kit Receptor Tyrosine Kinase" J. Biol. Chem. 266(30):19908-19916.

Lev, et al. (1991) "A Specific Combination of Substrates is Involved in Signal Transduction by the kit-Encoded Receptor" EMBO J.

10:647-654.

Ben-Levy, et al. (1992) "A oncogenic point mutation confers High Affinity
Ligand Binding to the neu Receptor" J. Biol. Chem. 267:17304-17313.

Bonnerot, et al. (1992) "Role of associated .gamma.-Chain in Tyrosine
Kinase Activtion via Murine FcRIII" EMBO J. 11(7):2747-2757.

Fields, S. and Song, O (1989) "A Novel Genetic System to Detect
Protein-Protein Interactions" Nature340:245-246.

Palmiter, et al. (1985) "Transgenic Mice" Cell 41:343-345.

Itoh, et al. (1993) "Effect of bcl-2 on Fas Antigen-Mediated Cell Death" J.
Immunol. 151:621-627.

Itoh and Nagata (1993) "A Novel Protein Domain Required for Apoptosis"
J.B.C. 268:10932.

Ptashne, et al. (1990) "Activators and Targets" Nature 346:329-331.

Watanbe-Fukunaga, et al. (1992) "Lymphoproliferation Disorder in Mice
Explained by Defects in Fas Antigen that Mediates Apoptosis"Nature 356:314-317.

Engel, et al. (1992) "High-Efficiency Expression and Solubization of
Functional T-Cell antigen Receptor Heterodimers" Science 256:1318-1321.

Gottschalk, et al. (1992) "The Carboxy Terminal 100 Amino Acid Portion of
the Insulin Receptor is Important for Insulin Signaling to Pyruvate
Dehydrogenase" Biochem & Biophys Res Comm 189:906-911.

Howard, et al. (1992) "The CD3.zeta. Cytoplamsic Domain Meiates CD2-Induced

T Cell Activation" J. Exp. Med. 176:139-145.

Kruskal, et al. (1992) "Phagocytic Chimeric Receptors Require Both
Transmembrane and Cytoplasmic Domains from the Mannos Receptor" J. Exp. Med.
176:1673-1680.

Lee, et al. (1992) "Functional Dissection of Structural Domains in the
Receptor for Colony Stimulating Factor-1" J. Biol. Chem.
267:16472-16483.

Mares, et al. (1992) "A Chimera between Platelet-Derived Growth Factor
.beta.-receptor and Fibroblast Growth Factor Receptor-1 Stimulates Pancreatic
.beta.-DNA Synthesis in the Presence of PDGF-BB" Growth Factors 6:93-101.

Seedorf, et al. (1992) "Differential effects of carboxy-terminal sequence
deletions on platelet-derived growth factor receptor signaling activites and
interactions with cellular substrates" Mol. Cell. Biol.
12:4347-4356.

Venkitaraman, et al. (1992) "Interleukin 7 receptor functions by recruiting
the tyrosine kinase p59.sup.tym through a segment of its cytoplasmic tail" PNAS
USA 89:12083-12087.

Zhang, et al. (1992) "The insulin receptor-related receptor" J. Biol. Chem.
267:18320-18328.

Cantley, et al. (1991) "Oncogenes and signal transduction" Cell 64:281-302.

Yarden, et al. (1988) "Growth factor receptor tyrosine kinases" Ann. Rev.
Biochem. 57:443-478.

Romeo, et al. (1991) "Cellular immunity to HIV activated by CD4 fused to T
cell of Fc receptor polypeptides" Cell 64:1037-1046.

Levaslaiho, et al. (1990) "Regulation by EGF is maintained in an overexpressed chimeric EDGR/neu receptor tyrosine kinase" J. Cell. Biochem. 42:123-133.

Lev, et al. (1990) "Receptor functions and ligand-dependent transforming potential of a chimeric kit proto-oncogene" Mol. Cell Biol. 10(11):6064-6068.

Seedorf, et al. (1991) "Analysis of platelet-derived growth factor receptor domain function using a novel chimeric receptor approach" J. Biol. Chem. 266:12424-12431.

Fuh, et al. (1992) "Rational design of potent antagonists to the human growth hormone receptor." Science 256:1677-1680.

Lehtola, et al. (1992) "A chimeric EGFR/neu receptor in functional anaylsis of the neu oncoprotein." Acta Oncologia 31(2):147-150.

Wennstrom, et al. (1992) "The platelet-derived growth factor beta-receptor kinase insert confers specific signaling properties to a chimeric fibroblast growth factor receptor." J. Biol. Chem. 267:13749-13756.

Reins, et al. (1993) "Anti-epidermal growth factor receptor monoclonal antibodies affecting signal trandsduction." J. Cell. Biol. 51:236-248.

Friedman and Weissman (1991) "Two Cytoplasmic Candidates for Immunophilin Action are Revealed by Affinity for a New Cyclophilin: One in the Presence and One in the Presence and One in the Absence of CsA." Cell 66:799.

Liu et al. (1991) "Calcineurin Is a Common Target of Cyclophilin-Cyclosporin A and FKBP-FK506 Complexes." Cell 66:807.

Larson and Nuss (1993) "Cyclophilin-dependent

stimulation of transcription
by cyclosporin A." PNAS 90:148.

Edalji et al. (1992) "High-Level Expression of Recombinant Human FK-Binding
Protein from a Fusion Precusor" J. Prot. Chem 11:213.

Fischer et al. (1992) "Mip protein of Legionella pneumophila exhibits
peptidyl-propyl-cis/trans isomerase (Pplase) activity." Mol. Microbiol. 6:1375.

Sampson and Gotschlich (1992) "Neisseria meningitidis encodes an
FK506-inhibitable rotamase" PNAS 89:1164.

Price et al. (1991) "Human cyclophilin B: A second cyclophilin gene encodes
a peptidyl-prolyl isomerase with a signal sequence." PNAS 88:1903.

Haendler et al. (1987) "Yeast cyclophilin: isolation and characterization
of the protein, cDNA and gene." EMBO J 6:947.

Zydowsky et al. (1992) Overexpression, purification, and characterization
of yeast cyclpohilins A and B. Protein Sci 1:961.

Liu (1993) "FK506 and cyclosporin, molecular probes for studying
intracellular signal transduction." Immunology Today 14:290.

Maki, et al. (1990) "Complementary DNA encoding the human T-cell
FK506-binding protein, a peptidylprolyl cis-trans isomerase distinct from
cyclophilin." Proc. Natl. Acad. Sci. USA 87:5440.

Standaert, et al. (1990) "Molecular cloning and overexpression of the human
FK506-binding protein FKBP" Nature 346:671.

Walsh, et al. (1992) "Cyclosporin A, the Cyclophilin Class of
Peptidylprolyl Isomerases, and Blockade of T Cell Signal Transduction" The

Journal of Biological Chemistry 267:13115.

Jin, et al. (1991) "Molecular cloning of a membrane-associated human FK506- and rapamycin-binding protein, FKBP-13" Proc. Natl. Acad. Sci. USA 88:6677.

Hung and Screiber (1992) "cDNA Cloning of a Human 25 kDa FK506 and Rapamycin Binding Protein" Biochemical and Biophysical Research Communications 184:733.

Haendler, et al. (1989) "Yeast cyclophilin: isolation and characterization of the protein, cDNA and gene" Gene 83:39.

Zydowsky, et al. (1992) "Active site mutants of human cyclophilin: A separate peptidyl-prolyl isomerase activity from cyclosporin A binding and calcineurin inhibition" Protein Science 1:1092.

Bergsma et al. (1991) "The Cyclophilin Mulitgene Family of Peptidyl-Prolyl Isomerase" J. Biol. Chem. 266:23204.

Tanida et al. (1991) "Yeast Cyclophilin-related gene encodes a nonessential second peptidyl-prolyl cis-trans isomerase with the secretory pathway" Transplantation Proceedings 23:2856.

Liu et al. (1990) "Cloning expression, and purification of human cyclophilin in Escherichia coli and assessment of the catalytic role of cysteines by site-directed mutagenesis" PNAS 87:2304.

ART-UNIT: 166

PRIMARY-EXAMINER: Elliott; George C.

ASSISTANT-EXAMINER: Schwartzman; Robert

ABSTRACT:

We have developed a general procedure for the regulated

(inducible)
dimerization or oligomerization of intracellular proteins
and disclose methods
and materials for using that procedure to regulatably
initiate cell-specific
apoptosis (programmed cell death) in genetically engineered
cells.

64 Claims, 35 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 34

US-PAT-NO: 5994313
DOCUMENT-IDENTIFIER: US 5994313 A

TITLE: Regulated apoptosis

DATE-ISSUED: November 30, 1999

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Crabtree; Gerald R.	Woodside	CA	N/A	N/A
Schreiber; Stuart L.	Cambridge	MA	N/A	N/A
Spencer; David M.	Los Altos	CA	N/A	N/A
Wandless; Thomas J.	Cambridge	MA	N/A	N/A
Belshaw; Peter	Somerville	MA	N/A	N/A

ASSIGNEE INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY	TYPE CODE
Board of Trustees of the Leland S. Stanford, Jr. Univ.	Stanford	CA	N/A	N/A	02
President and Fellows of Harvard College	Cambridge	MA	N/A	N/A	02

APPL-NO: 08/ 483898

DATE FILED: June 7, 1995

PARENT-CASE:

CROSS-REFERENCE TO RELATED APPLICATIONS This application is a divisional of U.S. Ser. No. 08/292,597, filed Aug. 18, 1994 (now U.S. Pat. No. 5,834,266), which is a continuation-in-part of U.S. Ser. No. 08/179,143, filed Jan. 7, 1994, (now abandoned) which in turn is a

continuation-in-part of
U.S. Ser. No. 08/093,499, filed Jul. 16, 1993 (now abandoned). U.S. Ser.
No. 08/292,597 is also a continuation-in-part of U.S. Ser. No. 08/196,043,
filed Feb. 14, 1994 (now abandoned), which in turn is a continuation-in-part
of U.S. Ser. No. 08/179,748, filed Jan. 7, 1994 (now abandoned), which in
turn is a continuation-in-part of U.S. Ser. No. 08/092,977, filed Jul. 16,
1993 (now abandoned), which in turn is a continuation-in-part of U.S. Ser.
No. 08/017,931, filed Feb. 12, 1993 (now abandoned).

INT-CL: [06] A61K031/70,A61K038/13 ,A61K048/00 ,C12N005/10

US-CL-ISSUED: 514/31;424/93.21 ;435/325 ;435/372.3 ;514/9

US-CL-CURRENT: 514/31; 424/93.21 ; 435/325 ; 435/372.3 ; 514/9

FIELD-OF-SEARCH: 435/69.1; 435/325 ; 435/375 ; 435/7.1 ; 435/372.3 ; 552/502
; 514/169 ; 514/9 ; 514/10 ; 514/14 ; 514/31 ; 800/2 ; 424/93.21

REF-CITED:

U.S. PATENT DOCUMENTS

PAT-NO	ISSUE-DATE	PATENTEE-NAME	US-CL
5171671	December 1992	Evans et al.	435/69.1
	N/A	N/A	
5589362	December 1996	Bujard et al.	435/69.1
	N/A	N/A	

FOREIGN PATENT DOCUMENTS

FOREIGN-PAT-NO	PUBN-DATE	COUNTRY	US-CL
23550	November 1993	WO	

OTHER PUBLICATIONS

Durand et al., "Characterization of Antigen Receptor Response Elements
Within the Interleukin-2 Enhancer"; Mol. Cell Biol. 8(2):1715-1724 (1988).

Letourneur and Klausner, Activation of T Cells by a Tyrosine Kinase
Activation Domain in the Cytoplasmic Tail of CD3 .epsilon.; Science 255:79-82
(1992).

Flanagan et al., "Nuclear Association of a T-Cell Transcription Factor
Blocked by FK-506 and Cyclosporin A"; Nature 352:803-807
(1991).

Fisher et al., "On the Remarkable Propensity for Carbon-Carbon Bond
Cleavage Reactions in the C.sub.8 -C.sub.10 Region of FK-506"; J. Org. Chem.
56:2900-2907 (1991).

VanRheenen et al., "An Improved Catalytic OsO.sub.4 Oxidation of Olefins to
Cis-1,2-Glycols Using Tertiary Amine Oxides as the Oxidant"; Tetrahedron
Letters 23:1973-1976 (1976).

Fields, S. and Song, O., "A novel genetic system to detect protein--protein
interactions"; Nature 340:245-246 (1989).

Ghosh et al., "N,N'-Disuccinimidyl Carbonate: A Useful Reagent for
Alkoxycarbonylation of Amines"; Tetrahedron Letters
33:2781-2784 (1992).

Zelle et al., "A Systematic Degradation of Zincophorin: A Stereoselective
Synthesis of the C.sub.17 -C.sub.25 Fragment"; J. Org. Chem. 51:5032-5036
(1986).

Krishnamurthy, "Lithium Tris[(3-ethyl-3-pentyl)oxy]aluminum Hydride. A New
Remarkably Chemoselective Reagent for the Reduction of Aldehydes in the
Presence of Ketones"; J. Org. Chem. 46:4628-4629 (1981).

Nussbaumer et al., C9-Imino and C10-Amino Derivatives of Ascomycin
(21-Ethyl-FK506); Tetrahedron Letters 33:3845-3846 (1992).

Evans et al., "Rhodium(I)- and Iridium(I)-Catalyzed Hydroboration
Reactions: Scope and Synthetic Applications"; J. Am. Chem. Soc. 114:6671-6679
(1992).

Evans et al., "Mechanistic Study of the Rhodium(I)-Catalyzed Hydroboration
Reaction"; J. Am. Chem. Soc. 114:6679-6685 (1992).

Traber et al., "Cyclosporins--New Analogues by Precursor Directed
Biosynthesis"; J. Antibiotics 42:591-597 (1989).

Patchett et al., "Analogs of Cyclosporin A Modified at the D-ALA.sup.8
Position"; J. Antibiotics 45:94-102 (1992).

Donald et al., "C10 N-Acyl Modified FK-506: A Possible Hybrid Analogue of
the Transition State of Peptidyl-Prolyl Cis-Trans Isomerization"; Tetrahedron
Letters 31:1375-1378 (1991).

Byrn et al., "Biological Properties of a CD4 Immunoadhesin"; Nature
344:667-670 (1990).

Lanier et al., "Co-association of CD3.zeta. with a Receptor (CD16) for IgG
Fc on Human Natural Killer Cells"; Nature 342:803-805 (1989).

Mattila et al., "The Actions of Cyclosporin A and FK506 Suggest a Novel
Step in the Activation of T Lymphocytes"; EMBO J. 9(13):4425-4433 (1990).

Verweij et al., "Cell Type Specificity and Activation Requirements for
NFAT-1 (Nuclear Factor of Activated T-Cells) Transcriptional Activity
Determined by a New Method Using Transgenic Mice to Assay Transcriptional
Activity of an Individual Nuclear Factor"; J. Biol. Chem. 265(26):15788-15795
(1990).

Clark et al., "The B Cell Antigen Receptor Complex: Association of Ig-.alpha. and Ig-.beta. with Distinct Cytoplasmic Effectors"; Science 258:123-126 (1992).

Shaw et al., "Identification of a Putative Regulator of Early T Cell Activation Genes"; Science 241:202-205 (1988).

Weissman et al., "Molecular Cloning and Chromosomal Localization of the Human T-Cell Receptor .zeta. Chain: Distinction from the Molecular CD3 Complex"; Proc. Natl. Acad. Sci. USA 85:9709-9713 (1988).

Emmel et al., "Cyclosporin A Specifically Inhibits Function of Nuclear Proteins Involved in T-Cell Activation"; Science 246:1617-1620 (1989).

Eberle and Nuninger, "Synthesis of the Main Metabolite (OL-17) of Cyclosporin A"; J. Org. Chem. 57:2689-2691 (1992).

Irving and Weiss, "The Cytoplasmic Domain of the T Cell Receptor .zeta. Chain is Sufficient to Couple to Receptor-Associated Signal Transduction Pathways"; Cell 64:891-901 (1991).

Kinet, "Antibody-Cell Interactions: Fc Receptors"; Cell 57:351-354 (1989).

Orloff et al., "Family of Disulphide-Linked Dimers Containing the .zeta. and .eta. Chains of the T-Cell Receptor and the .gamma. Chain of Fc Receptors"; Nature 347:189-191 (1990).

Itoh and Nagata, "A Novel Protein Domain Required for Apoptosis", JBC 268:10932-10937 (1993).

Ptashne et al., "Activators and Targets", Nature 346:329-331 (1990).

Schreiber, "Chemistry and Biology of the Immunophilins and Their Immunosuppressive Ligands", Science 251:283-287 (1991).

Palmiter et al., "Transgenic Mice", Cell 41:343-345 (1985).

Itoh et al., "Effect of bc1-2 on Fas Antigen-Mediated Cell Death", Journal of Immunology 151:621-627 (1993).

Spencer et al (1993) Science 262:1019-1024.

Watson et al. (1994) The G-Protein Linked Receptor Facts Book, Academic Press Limited, San Diego, pp. X-Xi, 3-6.

Travis (1993) Science 262:989.

Metzger et al. (1995) Proc. Natl. Acad. Sci. USA 92:6991-6995.

Logie et al. (1995) Proc. Natl. Acad. Sci. USA 92:5940-5944.

Kappel et al. (1992) Current Opinion in Biotechnology 3:548-553.

Spencer et al. (1994) J. Cellular Biochemistry. Supp. 18A:252.

Selvakumaran M., et al, "Myeloblastic leukemia cells conditionally blocked by myc-estrogen receptor chimeric transgenes for terminal differentiation coupled to growth arrest and apoptosis", (1993) Blood 81(9):2257-62.

Weiss, A., "T cell antigen receptor signal transduction: a tale of tails and cytoplasmic protein-tyrosine kinases." (1993) Cell, 73(2):209-12.

Rudert F., et al, "Apoptosis in L929 cells expressing a CD40/Fas chimeric receptor: dissociation of stimulatory from inhibitory death signalling functions.", (1994) Biochem Biophys Res Commun,

204(3):1102-10.

ART-UNIT: 166

PRIMARY-EXAMINER: Elliott; George C.

ASSISTANT-EXAMINER: Schwartzman; Robert

ABSTRACT:

We have developed a general procedure for the regulated (inducible) dimerization or oligomerization of intracellular proteins and disclose methods and materials for using that procedure to regulatably initiate cell-specific apoptosis (programmed cell death) in genetically engineered cells.

48 Claims, 32 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 34

US-PAT-NO: 5741899
DOCUMENT-IDENTIFIER: US 5741899 A

TITLE: Chimeric receptors comprising janus kinase for regulating cellular pro
liferation

DATE-ISSUED: April 21, 1998

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Capon; Daniel J.	Hillsborough	CA	N/A	N/A
Tian; Huan	Cupertino	CA	N/A	N/A
Smith; Douglas H.	Foster City	CA	N/A	N/A
Winslow; Genine A.	Hayward	CA	N/A	N/A
Siekevitz; Miriam	New York	NY	N/A	N/A

ASSIGNEE INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY	TYPE CODE
Cell Genesys, Inc.	Foster City	CA	N/A	N/A	02

APPL-NO: 08/ 481003

DATE FILED: June 7, 1995

PARENT-CASE:

This application is a continuation of application Ser. No. 08/382,846, filed
Feb. 2, 1995, which is pending.

INT-CL: [06] C12N015/62,C12N005/10 ,C07K019/00 ,C07K014/705

US-CL-ISSUED: 536/23.4;435/69.7 ;435/320.1 ;435/325 ;435/377 ;530/350
;530/387.3

US-CL-CURRENT: 536/23.4; 435/320.1 ; 435/325 ; 435/377 ; 435/69.7 ; 530/350
; 530/387.3

FIELD-OF-SEARCH: 536/23.4; 435/69.7 ; 435/240.2 ; 435/320.1 ; 435/325 ; 435/377
; 530/387.3 ; 530/350

REF-CITED:

U.S. PATENT DOCUMENTS

PAT-NO	ISSUE-DATE	PATENTEE-NAME	US-CL
5359046	October 1994	Capon et al.	536/23.4
	N/A	N/A	
5470730	November 1995	Greenberg et al.	435/172.3
	N/A	N/A	
5504000	April 1996	Littman et al.	435/194
	N/A	N/A	

FOREIGN PATENT DOCUMENTS

FOREIGN-PAT-NO	PUBN-DATE	COUNTRY	US-CL
0340793	August 1989	EP	
WO9319163	September 1993	WO	
WO9429438	December 1994	WO	

OTHER PUBLICATIONS

Spencer et al. (1993) Science 262:1019-1024.

Travis (1993) Science 262:989.

Nakamura et al. (1994) Nature 369: 330-333.

Heinzel et al., Use of Simian Virus 40 replication to amplify Epstein-Barr virus shuttle vectors in human cells, J. Virol. 62:3738-3746 (1988).

Kishimoto et al., Cytokine Signal Transduction, Cell 76:253-262 (1994).

Miyazaki et al., Functional activation of Jak1 and Jak3 by selective association with IL-2 receptor subunits, Science 266:1045-1047 (1994).

Morgan and Anderson, Human Gene Therapy, Ann. Rev. Biochem. 62:191-217 (1993).

Mulligan, The Basic Science of Gene Therapy, Science 360:926-930 (1993).

Niehuis et al., Gene Transfer into Hematopoietic Stem Cells, Cancer 67:2700-2704 (1991).

Paul, Tumor Immunology, Fundamental Immunol., Chap. 34, pp. 923-955 (1989).

Orkin et al., Report and Recommendations of the Panel to Assess the NIH Investment in Research on Gene Therapy (1995).

Riddell et al., Genetically Modified T-Cell Clones as a Treatment for Human Viral Diseases, Soc. Biol. Therapy, (Meeting Abstract), p. 50 (1993).

Sakai et al., Signal Transduction by a CD16/CD7/Jak2 fusion Protein, J. Biol. Chem. 270:18420-18427 (1995).

Stancovski et al., Targeting of T Lymphocytes to Neu/Her-2-expressing Cells using chimeric Single Chain Fv Receptors, J. Immunol. 151:6577-6582 (1993).

Weatherall, Scope and limitations of Gene Therapy, British med. Bull. 51:1-11 (1995).

ART-UNIT: 182

PRIMARY-EXAMINER: Walsh; Stephen

ASSISTANT-EXAMINER: Pak; Michael D.

ABSTRACT:

The present invention is directed to novel chimeric proliferation receptor proteins and DNA sequences encoding these proteins where the chimeric proteins

are characterized in three general categories. In one category, the novel chimeric proteins comprise at least three domains, namely, an extracellular inducer-responsive clustering domain capable of binding an extracellular inducer that transmits a signal to a proliferation signaling domain, a transmembrane domain and a proliferation signaling domain that signals a host cell to divide. In the second category, the novel chimeric proteins comprise at least two domains, namely, an intracellular inducer-responsive clustering domain capable of binding an intracellular inducer and a proliferation signaling domain that signals the cell to divide. In yet a third category, a novel hybrid chimeric protein receptor is contemplated that contains an intracellular or extracellular inducer domain, a transmembrane domain, a proliferation signaling domain and an effector signaling domain in a single chain molecule. Whether the binding domain is intracellular or extracellular, the binding of inducer to these novel chimeric receptor proteins induces the clustering of the binding domains to each other and further signals the cell to proliferate, and optionally, signal an effector function. The present invention further relates to expression vectors containing the nucleic acids encoding the novel chimeric receptors, cells expressing the novel chimeric receptors and therapeutic methods of using cells expressing these novel receptors for the treatment of cancer, infectious disease and autoimmune diseases, for example.

12 Claims, 16 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 6

US-PAT-NO: 5614397
DOCUMENT-IDENTIFIER: US 5614397 A

TITLE: Method and compositions for modulating lifespan of hematolymphoid cells

DATE-ISSUED: March 25, 1997

INVENTOR-INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY
Weissman; Irving	Redwood City	CA	N/A	N/A
Lagasse; Eric	Palo Alto	CA	N/A	N/A

ASSIGNEE INFORMATION:

NAME	CITY	STATE	ZIP CODE	COUNTRY	TYPE CODE
Board of Trustees of the Leland Stanford Junior University	Stanford	CA	N/A	N/A	02

APPL-NO: 08/ 200016

DATE FILED: February 22, 1994

INT-CL: [06] C12N015/85,C12N005/10

US-CL-ISSUED: 435/172.3;435/325 ;435/355

US-CL-CURRENT: 435/458; 435/325 ; 435/355

FIELD-OF-SEARCH: 435/240.2; 435/240.21 ; 435/172.3 ; 514/44 ; 424/93.21

FOREIGN PATENT DOCUMENTS

FOREIGN-PAT-NO	PUBN-DATE	COUNTRY	US-CL
WO93/25683	December 1993	WO	

OTHER PUBLICATIONS

Hockenberry et al., "Bcl-2 Functions in an Antioxidant

Pathway to Prevent
Apoptosis," Cell (1993) 75:241-251.

Ellis et al., "Genetic Control of Progammed Cell Death in the Nematode C.
elegans," Cell (1986) 44:817-829.

Hengartner, M.O., "Caenorhabditis elegansgene ced-9 protects cells from
programmed cell death," Nature (1992) 356:494-499.

Nakayama et al., "Disappearance of the Lymphoid System in Bcl-2 Homozygous
Mutant Chimeric Mice," Science (1993) 261:1684.

Snouwaert et al., "An Animal Model for Cystic Fibrosis Made by Gene
Targeting," Science (1992) 257:1083-1088.

Dorin et al., "Cystic fibrosis in the mouse by targeted insertional
mutagenesis, " Nature (1992) 359:211-215.

Lagasse et al., "Cloning and Expression of Two Human Genes Encoding
Calcium-Binding Proteins That Are Regulated During Myeloid Differentiation,"
Mol. Cell. Biol. (1988) 8:2402-2410.

Lagasse et al., "Mouse MRP8 and MRP14, Two Intracellular Calcium-Binding
Proteins Associated with the Development of the Myeloid Lineage," Blood (1992)
79:1907.

Spencer et al., "Controlling Signal Transduction with Synthetic Ligands,"
Science (1993) 262:1019-1024.

Porter et al., "X-Linked Chronic Granulomatous Disease: Correction of NADPH
Oxidase Defect by Retrovirus-Mediated Expression of gp91-phox," Blood (1993)
82:2196-2202.

Cobbs et al., "Retroviral Expression of Recombinant p47.sup.phox Protein by
Epstein-Barr Virus-Transformed B Lyphocytes From a Patient

With Autosomal
Chronic Granulomatous Disease," Blood (1992) 79:829-1835.

Erikson et al., "Identification of a Thermolabile Component of the Human
Neutrophil NADPH Oxidase," J. Clin. Invest. (1992) 89:1587-1595.

DiBartolomeo et al., "Reconstitution of normal neutrophil function in
chronic granulomatous disease by bone marrow transplantation," Bone Marrow
Transplantation (1989) 4:695-750.

Lomax et al., "Selective Defect in Myeloid Cell Lactoferrin Gene Expression
in Neutrophil Specific Granule Deficiency," J. Clin. Invest. (1989) 83:514-519.

Veis et al., "Bcl-2-Deficient Mice Demonstrate Fulminant Lymphoid
Apoptosis, Polycystic Kidneys, and Hypopigmented Hair," Cell (1993) 75:229.

Bright et al., Biosciences Reports, vol. 14, 1994, pp. 67-81.

Nowicki et al., Cellular Immunology, vol. 132, 1991, pp. 115-126.

Sarin et al., J. Experimental Medicine, vol. 178, 1993, pp. 1693-1700.

Gong et al., J. Cellular Phyriology, vol. 157, 1993, pp. 263-270.

ART-UNIT: 185

PRIMARY-EXAMINER: Ketter; James S.

ABSTRACT:

Methods and compositions for modifying the lifespan of progeny cells of
mammalian hematopoietic stem cells, particularly myeloid series cells, are
provided. Transgenic nonhuman mammals also are provided which produce

transgenic myeloid cells having an altered lifespan.

10 Claims, 20 Drawing figures

Exemplary Claim Number: 1

Number of Drawing Sheets: 16